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SENTRY Antimicrobial Surveillance Program Report:
 Latin American and Brazilian Results for 1997 through 2001
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Juliana B. Silva1, Antonio C. Pignatari1 and the Division of Infectious Diseases, Federal University of
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The alarming emergence and spread of antimicrobial resistance among common bacteria
threatens the effectiveness of therapy for many infections. Surveillance of antimicrobial resistance
is essential to identify the major problems and guide adequate control measures. Several resistance
surveillance programs have been implemented in North America and Europe in the last decade;
however, very few programs have assessed antimicrobial resistance in Latin American countries.
The SENTRY Antimicrobial Surveillance Program was initiated in 1997 and represents the most
comprehensive surveillance program in place at the present time worldwide. The SENTRY Program
collects consecutive isolates from clinically documented infections in more than 80 medical
centers worldwide (10 in Latin America). The isolates are collected according to the type of
infection (objectives) and susceptibility tested in a central microbiology laboratory by reference
broth microdilution methods according to NCCLS guidelines. The Program also incorporated
molecular typing (ribotyping and PFGE) and resistance mechanism analysis of selected isolates.
In this report we present a very broad analysis of the data generated by testing almost 20,000
bacterial isolates against more than 30 antimicrobial agents. The susceptibility results (MIC50,
MIC90 and % susceptible) are presented in 11 tables according to the organism and site of
infection. The data from Brazil, as well as the data from isolates collected in 2001, are analyzed
separately.  This report allows the evaluation of the activities numerous antimicrobial agents
against clinical isolates collected in Latin American countries.
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The importance of antimicrobial resistance among
nosocomial and community-acquired pathogens is
acknowledged worldwide. Well-designed antimicrobial
surveillance programs are essential in the fight against
these cases of resistance [1]. These programs provide
important information on the trend in microbial
occurrence in different geographical regions and
antimicrobial resistance patterns in nosocomial and
community-acquired infections. Such information has
the potential to guide therapeutic approaches for serious
infections, pending directions from local susceptibility
testing, and may have value in the prevention and
control of infection. However, in order to be effective,
surveillance data should be analyzed, tabulated and
rapidly presented to the medical community and
infection control workers.
The SENTRY Antimicrobial Surveillance Program
(SENTRY) was initiated in 1997 and was designed to
monitor the spectrum of microbial pathogens and
antimicrobial resistance trends for both nosocomial and
community-acquired infections on a global scale, by using
validated reference quality identification and susceptibility
testing methods in designated central laboratories [1-4].
Rapid communication and dissemination of information
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is a guiding principal of the SENTRY Program. This
report is a summary of the data collected in the Latin
American region during the first five years of the
SENTRY Program (1997 through 2001).
Material and Methods
Study design
The SENTRY Program was established to monitor
the important pathogens and antimicrobial resistance
patterns of nosocomial and community-acquired
infections via a broad network of sentinel hospitals
distributed by geographic location and size. The
collection of isolates was done according to the site of
infection and/or type of patient. The types of infections
that are monitored include bloodstream infections or
true bacteremia (BSI, objective A), community-
acquired respiratory tract infections (CARTI, objective
B), lower respiratory tract infections in hospitalized
patients (LRTI, objective C), skin and soft tissue
infections in hospitalized patients (SSTI, objective D),
urinary tract infections in hospitalized patients (UTI,
objective E), gastroenteritis (objective G), β-haemolytic
streptococci from community-acquired infections
(objective H), and assessment of pathogens and
resistance patterns among infected patients in the
intensive care unit (ICU, objective I). Objectives G, H
and I were introduced into the program in 2001.
Each participating center contributed results
(organism identification, date of isolation,
antimicrobial susceptibility profile, etc.) for the first
20 consecutive episodes of BSI per month from
January 1997 to December 2001, 100 consecutive
episodes of LRTI and CARTI per year from 1997
to 2001, 50 consecutive isolates from SSTI per year
from 1997 to 2000, and 50 consecutive isolates
from UTI per year from 1997 to 1999 and in 2001,
25 consecutive isolates of organisms considered
producers of diarrheal diseases (gastroenteritis)
collected in 2001, 25 consecutive β-haemolytic
streptococci isolated from community-acquired
infections in 2001, and 50 consecutive and clinically
relevant bacterial isolates from patients hospitalized
in the ICU in 2001. Just one isolate per patient was
included in the study and all isolates were saved on
transport swabs and sent to the monitoring center
(Iowa, USA) for storage and further characterization
by reference identification and susceptibility testing
methods. We evaluated all the isolates that were
recovered and the data collected from January 1997
to December 2001.
Participating centers
The laboratories were distributed in various cites of
six countries: Sao Paulo, Rio de Janeiro, Florianopolis,
Porto Alegre, and Brasilia, Brazil; Buenos Aires and
San Isidro, Argentina; Santiago (two centers), Chile;
Medellin, Colombia; Mexico City, Mexico; and
Montevideo, Uruguay. In 1998, the center located in
Montevideo was replaced by a center in Caracas,
Venezuela; and in 1999 the Brazilian center located in
Rio de Janeiro was replaced by another Brazilian center
in Porto Alegre, which is also located in the South region
of Brazil. In 2001, the center located in Mendellin,
Colombia was replaced by a center located in Brasilia,
Brazil. The selection of participant centers was based
on the principle that they should be representative in
their respective geographic region.
Species identification
All isolates were identified at the participating
institution by the routine methodology in use at each
laboratory. On receipt at the monitoring center, isolates
were subcultured on blood agar to ensure viability and
purity. Species identification was confirmed by
standardized methods or performed by using the Vitek
System (bioMérieux, Hazelwood, MO) or API
(bioMérieux, Hazelwood, MO). Isolates were frozen
at -70°C until they were processed.
Susceptibility testing
Antimicrobial susceptibility testing of isolates was
performed by reference broth microdilution methods,
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as described by the National Committee for Clinical
Laboratory Standards (NCCLS) [5]. Microdilution
trays were purchased from TREK Diagnostics
(Cleveland, OH), MicroScan (West Sacramento,
CA), and PML Microbiologicals (Wilsonville, OR).
Antimicrobial agents were obtained from their
respective manufactures as laboratory grade powder
and included cephalosporins (cefepime, cefuroxime,
cefotaxime, ceftriaxone, ceftazidime, cefazolin,
cefoxitin, cefaclor, and cefixime), penicillins (ampicillin,
penicillin, amoxicillin, and oxacillin), β-lactamase
inhibitor combinations (amoxicillin-clavulanate,
ticarcillin-clavulanate, and piperacillin-tazobactam),
carbapenems (imipenem and meropenem), a
monobactam (aztreonam), fluoroquinolones
(ciprofloxacin, levofloxacin, gatifloxacin, and
garenoxacin [formerly BMS 284756]),
aminoglycosides (amikacin, gentamicin, and
tobramycin), macrolides (erythromycin, azithromycin,
and clarithromycin), glycopeptides (vancomycin and
teicoplanin), the oxazolidinone linezolid, the
streptogramin quinupristin-dalfopristin, and other drugs,
such as clindamycin, chloramphenicol, tetracycline,
rifampin, and trimethoprim-sulfamethoxazole. Quality
control was performed by testing E. coli American
Type Culture Collection (ATCC) 25922,
Pseudomonas aeruginosa ATCC 27853, and other
strains, as recommended by the NCCLS [5,6].
Interpretive criteria for each antimicrobial tested were
those published by the NCCLS [5,6].
Results
Almost 20,000 clinical isolates were analyzed
during this period, and the frequencies of the different
pathogens were investigated (Table 1). The
antimicrobial susceptibility data for the year 2001 were
analyzed separately (Tables 2-5), while the data for
the entire 5-year period was also compiled (Tables
6-11).
In addition, data collected in the participating
Brazilian centers were analyzed separately from the
data of the entire Latin American region (including
Brazil). Minimum antimicrobial concentrations that
inhibits 50% and 90% of the organism collection
(MIC50 and MIC90, respectively) were presented only
for the data of the entire region. Isolates collected
from bloodstream infections and from lower
respiratory tract infections (mainly pneumonia) in
hospitalized patients were also analyzed separately
(Tables 3, 5, 7 and 9).
Two groups of pathogens, streptococci and
extended-spectrum (ESBL)-producing strains, were
analyzed separately due to their importance in
community-acquired and nosocomial-acquired
infections, respectively. Table 10 presents the
antimicrobial susceptibility of streptococcal species,
while Table 11 presents the antimicrobial susceptibility
of ESBL-producing E. coli and Klebsiella
pneumoniae.
Discussion
We made a comprehensive analysis of the Latin
American SENTRY Program data collected during the
first five years of this global program. During this period,
SENTRY has provided valuable information worldwide
[2-4, 7-9]. The rapid publication of regional susceptibility
data concerning a large number of antimicrobial agents,
indexed by the site of infection, allowed the detection of
considerable geographical variation of the in vitro activity
of several antimicrobial agents and made evident the
emergence of important resistance patterns. These data
have been used to guide empirical therapy and the local
implementation of control or intervention measures. In
addition, SENTRY Program data has guided the
implementation of more focused, local surveillance studies,
which have been designed based on local resistance
problems detected by SENTRY Program results [10,11].
The SENTRY Program has shown that resistance
among Gram-negative bacteria seems to be much
higher in Latin America when compared to other regions
of the world, especially North America and Europe
[1,2]. On the other hand, some resistance problems
related to Gram-positive cocci, such as glycopeptide-
resistance among enterococci, and high-level penicillin-
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Pathogen (no total/Brazil)/ Latin America Brazil
MIC50 MIC90 % Susceptiblea % Susceptiblea
Acinetobacter spp. (166/90)
Cephalosporins
Ceftazidime >16 >16 30.1 28.9
Cefepime >16 >16 34.3 36.7
Other β-lactams
Aztreonam >16 >16 7.2 5.6
Ticarcillin/clavulanate 128 >128 39.8 30
Piperacillin/tazobactam >64 >64 27.7 31.1
Imipenem 1 >8 83.7 97.8
Meropenem 2 >8 81.9 96.7
Aminoglycosides
Amikacin >32 >32 38 35.6
Gentamicin >8 >/8 30.7 38.9
Tobramycin 16 >16 45.8 50
Fluoroquinolones
Ciprofloxacin >2 >2 28.3 33.3
Levofloxacin >4 >4 28.9 33.3
Gatifloxacin >4 >4 30.1 34.4
Garenoxacin >4 >4 29.5 34.4
Others
Tetracycline 8 >8 33.7 36.7
Trimethoprim/
sulfamethoxazole >2 >2 31.3 36.7
Polymyxin B <1 2 98.2 —
Enterobacter spp. (186/94)
Cephalosporins
Cefazolin >16 >16 4.3 4.3
Cefuroxime >16 >16 38.7 48.9
Cefoxitin >32 >32 2.2 2.1
Ceftriaxone 1 >32 61.3 73.4
Ceftazidime <2 >16 61.8 73.4
Cefepime <0.12 >16 84.9 95.7
Other β-lactams
Ampicillin >16 >16 2.7 3.2
Aztreonam 0.5 >16 60.2 72.3
Ticarcillin/clavulanate 16 >128 51.1 64.9
Piperacillin/tazobactam 4 >64 65.6 76.6
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Table 2. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-negative pathogens
isolated in the year 2001 througout Latin America and in Brazil alone
Antimicrobial agent
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Imipenem 0.5 1 99.5 98.9
Meropenem <0.06 0.25 98.9 97.9
Aminoglycosides
Amikacin 2 >32 84.9 91.5
Gentamicin <1 >8 67.7 81.9
Tobramycin 0.5 >16 62.4 78.7
Fluoroquinolones
Ciprofloxacin 0.03 >2 78 89.4
Levofloxacin 0.03 >4 78.5 91.5
Gatifloxacin 0.03 >4 79.6 92.6
Garenoxacin 0.12 >4 76.9 90.4
Others
Tetracycline <4 >8 71.5 81.9
Trimethoprim/
sulfamethoxazole <0.5 >2 68.8 77.7
Polymyxin B <1 >8 79.9 —
E. coli (457/158)
Cephalosporins
Cefazolin <2 16 85.6 89.2
Cefuroxime 4 8 90.6 93
Cefoxitin 4 8 92.8 93.7
Ceftriaxone <0.25 0.25 95.6 (5.5)b 98.1 (3.2)b
Ceftazidime <2 <2 96.1 (6.6)b 96.8 (3.8)b
Cefepime <0.12 0.25 97.2 98.1
Other β-lactams
Ampicillin >16 >16 40.9 41.1
Aztreonam 0.12 0.25 95.6 (5.5)b 97.5 (2.5)b
Ticarcillin/clavulanate 8 64 70.5 80.4
Piperacillin/tazobactam 1 4 95 96.8
Imipenem 0.12 0.12 99.8 100
Meropenem <0.06 <0.06 100 100
Aminoglycosides
Amikacin 2 4 97.2 100
Gentamicin <1 8 89.3 95.6
Tobramycin 1 8 89.7 95.6
Fluoroquinolones
Ciprofloxacin 0.01 >2 85.8 91.1
Levofloxacin 0.03 4 87.1 93
Gatifloxacin 0.03 4 87.1 92.4
Garenoxacin 0.03 >4 85.8 91.1
Others
Tetracycline <4 8 58.4 58.2
Trimethoprim/
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sulfamethoxazole <0.5 >2 52.3 44.3
Polymyxin B <1 <1 99.4 —
Haemophilus influenzae (319/129)
Cephalosporins
Cefazolin 8 16 NA NA
Cefuroxime 1 2 96.9 96.1
Cefoxitin 2 NA NA
Ceftriaxone 0.01 0.5 100 100
Ceftazidime <2 <2 100 100
Cefepime 0.06 0.12 100 100
Other β-lactams
Ampicillin <0.5 >4 81.5c 82.2c
Aztreonam 0.12 0.12 100 100
Piperacillin/tazobactam <0.5 <0.5 100 100
Imipenem 0.25 0.5 100 100
Meropenem 0.06 0.06 100 100
Macrolides
Azithromycin 1 2 99.6 99.2
Clarithromycin 8 8 93.4 91.4
Aminoglycosides
Amikacin 4 8 NA NA
Gentamicin 2 2 NA NA
Tobramycin 2 4 NA NA
Fluoroquinolones
Ciprofloxacin 0.03 0.03 100 100
Levofloxacin 0.03 0.03 100 100
Gatifloxacin 0.03 0.03 100 100
Garenoxacin 0.03 0.03 100 100
Others
Tetracycline <4 <4 80.3 93.8
Choranphenicol <2 <2 95.6 96.1
Trimethoprim/
sulfamethoxazole <0.5 >2 54.9 48.1
K. pneumoniae (292/143)
Cephalosporins
Cefazolin 4 >16 54.1 46.3
Cefuroxime 4 >16 56.5 54.5
Cefoxitin 4 16 83.6 83.9
Ceftriaxone 0.25 >32 65.4 (39.7)b 59.4 (43.4)b
Ceftazidime <2 >16 70.9 (37)b 65.7(42)b
Cefepime 0.12 >16 77.1 70.6
Other β-lactams
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Ampicillin >16 >16 3.8   2.8
Aztreonam 0.12 >16 64.7 (38)b 57.3 (43.4)b
Ticarcillin/clavulanate 16 >128 54.1 51.7
Piperacillin/tazobactam 2 >64 76 72.7
Imipenem 0.12 0.25 100 100
Meropenem <0.06 0.12 99 98.6
Aminoglycosides
Amikacin 2 32 83.6 86.7
Gentamicin <1 >8 63.7 62.9
Tobramycin 0.5 >16 58.6 55.9
Fluoroquinolones
Ciprofloxacin 0.03 >2 84.2 82.5
Levofloxacin 0.06 >4 86 82.5
Gatifloxacin 0.06 >4 86 82.5
Garenoxacin 0.12 >4 83.9 83.2
Others
Tetracycline <4 >8 66.8 64.3
Trimethoprim/
sulfamethoxazole <0.5 >2 67.1 60.1
Polymyxin B <1 <1 97.8
Moraxella catarrhalisd(63/16)
β-lactams
Ampicillin <2 4 0c 0c
Cefuroxime 1 2 100 100
Ceftriaxone 0.25 0.5 100 100
Cefepime 0.5 2 100 100
Macrolides
Azithromycin <0.12 <0.12 100 100
Clarithromycin <0.25 <0.25 100 100
Fluoroquinolones
Ciprofloxacin 0.03 0.03 100 100
Levofloxacin 0.03 0.03 100 100
Gatifloxacin 0.03 0.03 100 100
Garenoxacin 0.03 0.03 100 100
Others
Tetracycline <2 <2 95.2 100
Chloramphenicol <2 <2 100 100
Trimethoprim/
sulfamethoxazole <0.5 <0.5 90.5 81.3
Proteus spp.(32/-e)
Cephalosporins
Cefazolin 4 >16 62.5 d
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Cefuroxime 2 >16 100 d
Cefoxitin 4 4 100 d
Ceftriaxone 0.25 32  78.1 d
Ceftazidime <2 <2 100 d
Cefepime 0.12 >16 81.3 d
Other β-lactams
Ampicillin <2 >16 62.5 d
Aztreonam 0.12 1 96.9 d
Ticarcillin/clavulanate <1 8 100 d
Piperacillin/tazobactam <0.5 1 100 d
Imipenem 1 1 100 d
Meropenem 0.06 0.12 100 d
Aminoglycosides
Amikacin 2 8 96.9 d
Gentamicin <1 >8 75 d
Tobramycin 1 8 81.3 d
Fluoroquinolones
Ciprofloxacin 0.03 >2 78.1 d
Levofloxacin 0.06 >4 78.1 d
Gatifloxacin 0.12 >4 78.1 d
Garenoxacin 0.25 >4 68.8 d
Others
Tetracycline >8 >8   3.1 d
Trimethoprim/
sulfamethoxazole <0.5 >2 59.4 d
Polymyxin B >8 >8   0
P. aeruginosa (407/247)
Cephalosporins
Ceftazidime 8 >16 56.3 50.2
Cefepime 16 >16 54.8 46.6
Other β-lactams
Aztreonam 16 >16 41.3 36
Ticarcillin/clavulanate 64 >128 49.1 43.3
Piperacillin/tazobactam 32 >64 64.9 56.3
Imipenem 2 >8 62.2 51
Meropenem 2 >8 64.4 52.6
Aminoglycosides
Amikacin 8 >32 65.4 54.7
Gentamicin 8 >8 49.6 42.5
Tobramycin 1 >16 54.5 45.7
Fluoroquinolones
Ciprofloxacin 1 >2 49.9 46.2
Levofloxacin 4 >4 49.6 46.6
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Gatifloxacin 4 >4 46.4 43.3
Garenoxacin >4 >4 42.8 40.9
Others
Tetracycline >8 >8  1  0.4
Trimethoprim/
sulfamethoxazole >2 >2 5.4  5.3
Polymyxin B 2 2 97
Salmonella spp. (151/57)
Cephalosporins
Cefazolin <2 4 96.7 100
Cefuroxime 4 8 96.7 94.7
Cefoxitin 2 4 97.4 98.2
Ceftriaxone 0.25 0.25 100 100
Ceftazidime <2 <2 100 100
Cefepime <0.12 0.12 100 100
Other β-lactams
Ampicillin <2 >16 86.1 96.5
Aztreonam <0.12 0.12 100 100
Ticarcillin/clavulanate 2 16 90.7 100
Piperacillin/tazobactam 2 4 99.3 100
Imipenem 0.25 0.25 100 100
Meropenem <0.06 0.06 100 100
Aminoglycosides
Amikacin 1 2 100 100
Gentamicin <1 <2 96.7 94.6
Tobramycin 0.5 1 96.7 94.7
Fluoroquinolones
Ciprofloxacin 0.01 0.12 100 100
Levofloxacin 0.03 0.25 100 100
Gatifloxacin 0.03 0.12 100 100
Garenoxacin 0.06 0.25 100 100
Others
Tetracycline <4 >8 84.1 91.2
Trimethoprim/
sulfamethoxazole <0.5 <0.5 96 96.5
Serratia spp. (66/39)
Cephalosporins
Cefazolin >16 >16 1.5 0
Cefuroxime >16 >16 1.5 0
Cefoxitin 32 >32 3 2.6
Ceftriaxone 0.5 >32 69.7 69.2
Ceftazidime <2 >16 83.3 76.9
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Cefepime 0.25 >16 77.3 79.5
Other β-lactams
Ampicillin >16 >16   1.5    0
Aztreonam 0.5 >16 74.2 74.4
Ticarcillin/clavulanate 16 >128 50 43.6
Piperacillin/tazobactam 4 64 71.2 61.5
Imipenem 1 2 98.5 100
Meropenem 0.06 0.25 100 100
Aminoglycosides
Amikacin 4 >32 68.2 64.1
Gentamicin <1 >8 59.1 53.8
Tobramycin 4 >16 51.5 43.6
Fluoroquinolones
Ciprofloxacin 0.12 >2 72.7 59
Levofloxacin 0.25 >4 77.3 64.1
Gatifloxacin 0.25 >4 77.3 64.1
Garenoxacin 2 >4 60.6 53.8
Others
Tetracycline >8 >8    0   0
Trimethoprim/
sulfamethoxazole <0.5 >2 66.7 64.1
Polymyxin B >8 >8     0
Shigella spp. (202/84)
Cephalosporins
Cefazolin <2 4 99 98.8
Cefuroxime 2 4 99.5 98.8
Cefoxitin 2 4 99.5 98.8
Ceftriaxone <0.25 0.25 100 100
Ceftazidime <2 2 100 100
Cefepime 0.12 0.25 100 100
Other β-lactams
Ampicillin >16 >16 30.2 28.6
Aztreonam <0.12 0.12 99.5 98.8
Ticarcillin/clavulanate 32 32 83.7 86.9
Piperacillin/tazobactam 2 2 100 100
Imipenem 0.12 0.25 100 100
Meropenem 0.06 0.06 100 100
Aminoglycosides
Amikacin 4 8 100 100
Gentamicin <1 2 100 100
Tobramycin 1 2 100 100
Fluoroquinolones
Ciprofloxacin <0.01 <0.01 100 100
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Levofloxacin <0.03 0.03 100 100
Gatifloxacin <0.03 0.03 100 100
Garenoxacin <0.03 0.03 100 100
Others
Tetracycline <4 >8 53.5 71.4
Trimethoprim/
sulfamethoxazole >2 >2 26.7 15.5
Stenotrophomonas maltophilia (70/27)
Cephalosporins
Ceftazidime 8 >16 54.3 74.1
Cefepime 16 >16 30 44.4
Other β-lactams
Aztreonam >16 >16   2.9   0
Ticarcillin/clavulanate 32 128 45.7 63
Piperacillin/tazobactam 64 >64 21.7 29.6
Imipenem >8 >8    0   0
Meropenem >8 >8   2.9   7.4
Aminoglycosides
Amikacin >32 >32 10 11.1
Gentamicin >8 >8   5.7 11.1
Tobramycin >16 >16   7.1 11.1
Fluoroquinolones
Ciprofloxacin 1 >2 55.7 48.1
Levofloxacin 0.5 1 98.6 100
Gatifloxacin 0.5 1 98.6 100
Garenoxacin 1 4 88.6 81.5
Others
Tetracycline >8 >8 11.4 11.1
Trimethoprim/
sulfamethoxazole <0.5 <0.5 98.6 100
Polymyxin B 2 8 59.2 —
a. Interpreted by NCCLS 2003 criteria, when available [6] except for polymyxin B (< 2 for susceptible and > 4
for resistant);
b. Percentage of strain with MIC > 2 µg/mL, indicating possible ESBL production;
c. Percentage of non-β-lactamase producing strains. This value also represents the susceptibility rate to
amoxicillin.
d. Breakpoints for Haemophilus influenzae were used;
e. The results were not analyzed because the number of isolates was low (<10).
NA - Not applicable because there was no breakpoint established by the NCCLS [6].
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Pathogen (no total/Brazil)/ America Brazil
MIC50 MIC90 % Susceptiblea % Susceptiblea
S. aureus (669/329)
Cephalosporins
Ceftriaxone 4 >32 56.2 b 56.8b
Cefepime 4 >16 56.2 b 56.8b
Other β-lactams
Oxacillin 0.5 >8 56.2 56.8
Penicillin 16 >32   7.5   8.8
Amoxicillin/clavulanate <2 >16 56.2 b 56.8b
Piperacillin/tazobactam 2 >64 56.2 b 56.8b
Imipenem 0.06 >8 56.2 b 56.8b
MLS
Clindamycin 0.12 >8 60.5 59.9
Erythromycin 0.5 >8 50.7 48.9
Fluoroquinolones
Ciprofloxacin 0.5 >2 58.4 59.9
Levofloxacin 0.25 4 62.9 65
Gatifloxacin 0.12 4 89.7 86.9
Garenoxacin 0.03 1 97.8 97.9
Others
Gentamicin <2 >8 55.3 56.2
Rifampin <0.25 2 75.7 63.8
Chloramphenicol 8 >16 72.2 67.8
Tetracycline <4 >8 74.1 59.6
Doxycycline <0.5 >4 82.4 70.8
Trimethoprim/sulfamethoxale <0.5 >2 73.4 56.2
Vancomycin 1 1 100 100
Teicoplanin 1 2 99.9 99.7
Quinupristin/dalfopristin 0.25 0.5 100 100
Linezolid 2 2 100 100
CoNS (246/147)
Cephalosporins
Ceftriaxone 16 >32 20.7b 17.7b
Cefepime 4 >16 20.7b 17.7b
Other β-lactams
Oxacillin >8 >8 20.7 17.7
Penicillin 8 >32 11 10.2
Amoxicillin/clavulanate <2 >16 20.7b 17.7b
Piperacillin/tazobactam 4 >64 20.7b 17.7b
Imipenem 0.5 >8 20.7b 17.7b
MLS
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Table 3. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-positive cocci
isolated from hospitalized patients in 2001
Antimicrobial agent
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Clindamycin 0.12 >8 53.7 46.9
Erythromycin >8 >8 28.5 27.9
Fluoroquinolones
Ciprofloxacin 0.5 >2 52.4 44.9
Levofloxacin 0.5 >4 63 57.1
Gatifloxacin 0.25 2 93.1 92.5
Garenoxacin 0.06 2 95.1 94.6
Others
Gentamicin 8 >8 44.9 39.7
Rifampin 0.25 >2 74.8 70.7
Chloramphenicol 8 >16 68.3 59.2
Tetracycline <4 >8 77.6 74.1
Doxycycline <0.5 >4 88.6 87.8
Trimethoprim/sulfamethoxale 2 >2 48.8 35.4
Vancomycin 2 2 100 100
Teicoplanin 2 8 92.3 91.2
Quinupristin/dalfopristin 0.25 0.5 99.2 100
Linezolid 1 2 100 100
Enterococcus spp. (102 / 52)
β-lactams
Ampicillin <2 8 90.2 96.2
Penicillin 4 16 70.6 61.5
Amoxicillin/Clavulanate <2 4 90.2c 96.2c
Piperacillin/Tazobactam 4 >64 90.2c 96.2c
MLS
Erythromycin >8 >8   6.9   9.6
Fluoroquinolones
Ciprofloxacin 2 >2 46.1 38.5
Levofloxacin 2 >4 54.9 46.2
Gatifloxacin 1 >4 54.9 46.2
Garenoxacin 1 4 92.2 59.6
Others
Gentamicin (HL) <500 >1,000 55.9 42.3
Streptomycin (HL) <1,000 >2,000 62.7 82.7
Rifampin >2 >2 22.5 15.4
Chloramphenicol 8 >16 57.8 42.3
Tetracycline >8 >8 29.4 30.8
Doxycycline >4 >4 37.3 36.5
Trimethoprim/sulfamethoxale <0.5 >2 73.5 61.5
Vancomycin 1 2 93.1 92.3
Teicoplanin 0.12 0.5 94.1 92.3
Quinupristin/dalfopristin 8 >8   6.9   3.8
Linezolid 2 2 100 100
a. Interpreted by NCCLS 2003 criteria, when available [6]; b. Susceptibility is predicted by the oxacillin
result [6]; c. Susceptibility is predicted by the ampicillin result [6]; CoNS: coagulase-negative staphylo-
cocci; HL: High level aminoglycoside resistance screen.
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Table 4. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-negative
pathogens isolated in the year 2001 throughout Latin America and in Brazil alone, from patients with
bacteremia and pneumonia.
Pathogen/              % Susceptible strains (number of isolates tested)
Latin America Brazil
Bacteremia Pneumonia Bacteremia Pneumonia
(67) (60) (40) (29)
Acinetobacter spp.
Cephalosporins
Ceftazidime 44.8 21.7 47.5 13.8
Cefepime 49.3 23.3 55 17.2
Other β-lactams
Aztreonam 11.9   6.7 10   3.4
Ticarcillin/clavulanate 38.8 11.7 47.5 10.3
Piperacillin/tazobactam 44.8 15 50   6.9
Imipenem 88.1 86.7 97.5 100
Meropenem 85.1 85 97.5 96.6
Aminoglycosides
Amikacin 50.7 33.3 55 17.2
Gentamicin 46.3 21.7 57.5 24.1
Tobramycin 58.2 38.3 70 34.5
Fluoroquinolones
Ciprofloxacin 44.8 18.3 52.5 13.8
Levofloxacin 46.3 18.3 52.5 13.8
Gatifloxacin 46.3 20 52.5 17.2
Garenoxacin 46.3 20 52.5 17.2
Others
Tetracycline 47.8 21.7 52.5 17.2
Trimethoprim/
sulfamethoxazole 46.3 23.3 52.5 24.1
Enterobacter spp. Bacteremia Pneumonia Bacteremia Pneumonia
(117) (31) (59) (14)
Cephalosporins
Cefazolin     3.4  6.5 3.4   7.1
Cefuroxime 37.6 41.9 50.8 42.9
Cefoxitin   0.9 6.5   0   7.1
Ceftriaxone 63.2 51.6 78 57.1
Ceftazidime 61.5 61.3 72.9 57.1
Cefepime 86.3 77.4 96.6 92.9
Other β-lactams
Ampicillin   3.4   3.2   3.4   7.1
Aztreonam 62.4 51.6 72.9 57.1
Ticarcillin/clavulanate 51.3 51.6 67.8 57.1
Antimicrobial agents
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Piperacillin/tazobactam 67.5 61.3 83.1 57.1
Imipenem 100 96.8 100 92.9
Meropenem 99.1 96.8 98.3 92.9
Aminoglycosides
Amikacin 84.6 87.1 93.2 85.7
Gentamicin 69.2 67.7 83.1 85.7
Tobramycin 63.2 67.7 79.7 85.7
Fluoroquinolones
Ciprofloxacin 76.9 71 86.4 92.9
Levofloxacin 78.6 71 89.8 92.9
Gatifloxacin 79.5 71 91.5 92.9
Garenoxacin 77.8 71 88.1 92.9
Others
Tetracycline 67.5 83.9 79.7 85.7
Trimethoprim/
sulfamethoxazole 65 80.6 74.6 85.7
E. coli Bacteremia Pneumonia Bacteremia Pneumonia
(381) (14) (122) (a)
Cephalosporins
Cefazolin 87.4 64.3 93.4 a
Cefuroxime 91.6 85.7 95.1 a
Cefoxitin 93.4 85.7 93.4 a
Ceftriaxone 96.3 (4.7)b 92.9 (7.1)b 98.4 (2.5)b a
Ceftazidime 96.3 (5.8)b 100 (7.1)b 96.7 (3.3)b a
Cefepime 97.6 100 98.4 a
Other β-lactams
Ampicillin 41.7 28.6 45.1 a
Aztreonam 96.6 (4.7)b 92.3 (7.7)b 98.4 (1.6)b a
Ticarcillin/clavulanate 71.4 64.3 82 a
Piperacillin/tazobactam 95.8 85.7 96.7 a
Imipenem 100 92.9 100 a
Meropenem 100 100 100 a
Aminoglycosides
Amikacin 96.9 92.9 100 a
Gentamicin 90.3 85.7 95.9 a
Tobramycin 90.3 92.9 95.9 a
Fluoroquinolones
Ciprofloxacin 85.8 85.7 91.8 a
Levofloxacin 87.4 85.7 94.3 a
Gatifloxacin 87.1 92.9 93.4 a
Garenoxacin 85.8 92.9 91.8 a
Others
Tetracycline 58.8 42.9 61.5 a
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Trimethoprim/
sulfamethoxazole 52.8 57.1 45.1 a
K. pneumoniae Bacteremia Pneumonia Bacteremia Pneumonia
(176) (73) (90) (28)
Cephalosporins
Cefazolin 56.3 57.5 56.7 53.6
Cefuroxime 58.5 58.9 60 53.6
Cefoxitin 84.7 84.9 86.7 82.1
Ceftriaxone 66.5 (37.5)b 69.9 (39.7)b 64.4 (37.8)b 57.1 (42.9)b
Ceftazidime 69.9 (36.4)b 82.2 (28.8)b 70 (37.8)b 67.9 (39.3)b
Cefepime 79 82.2 75.6 71.4
Other β-lactams
Ampicillin   5.7   1.4   4.4   0
Aztreonam 64.8(36.9)b 74(32.9)b 62.2(35.6)b 57.1(42.9)b
Ticarcillin/clavulanate 56.3 57.5 55.6 50
Piperacillin/tazobactam 73.9 84.9 74.4 78.6
Imipenem 100 100 100 100
Meropenem 99.4 100 98.9 100
Aminoglycosides
Amikacin 84.1 89 90 85.7
Gentamicin 63.6 71.2 65.6 67.9
Tobramycin 59.7 63 62.2 50
Fluoroquinolones
Ciprofloxacin 84.7 90.4 86.7 85.7
Levofloxacin 86.9 91.8 86.7 85.7
Gatifloxacin 86.9 91.8 86.7 85.7
Garenoxacin 84.1 90.4 86.7 85.7
Others
Tetracycline 64.2 78.1 62.2 67.9
Trimethoprim/
sulfamethoxazole 65.3 78.1 58.9 71.4
P. aeruginosa Bacteremia Pneumonia Bacteremia Pneumonia
(119) (203) (58) (142)
Cephalosporins
Ceftazidime 68.1 50.7 69 40.8
Cefepime 66.4 49.8 65.5 38.7
Other β-lactams
Aztreonam 47.9 39.4 51.7 31
Ticarcillin/clavulanate 59.7 47.8 58.6 38.7
Piperacillin/tazobactam 79.8 56.2 75.9 46.5
Imipenem 79 53.7 75.9 41.5
Meropenem 80.7 57.3 77.6 45.1
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Aminoglycosides
Amikacin 73.9 61.1 70.7 51.4
Gentamicin 63 43.3 69 35.9
Tobramycin 67.2 50.7 69 41.5
Fluoroquinolones
Ciprofloxacin 60.5 43.3 70 40.1
Levofloxacin 60.5 42.9 70.7 40.8
Gatifloxacin 56.3 39.9 5.2 38
Garenoxacin 51.3 37.4 62.1 35.9
Others
Tetracycline   3.4   0   1.7   0
Trimethoprim/
sulfamethoxazole   2.5   3.9   3.4   7.7
Salmonella spp. Bacteremia Pneumonia Bacteremia Pneumonia
(35) (a) (a) (a)
Cephalosporins
Cefazolin 100 a a a
Cefuroxime 91.4 a a a
Cefoxitin 97.1 a a a
Ceftriaxone 100 a a a
Ceftazidime 100 a a a
Cefepime 100 a a a
Other β-lactams
Ampicillin 91.4 a a a
Aztreonam 100 a a a
Ticarcillin/clavulanate 91.4 a a a
Piperacillin/tazobactam 97.1 a a a
Imipenem 100 a a a
Meropenem 100 a a a
Aminoglycosides
Amikacin 100 a a a
Gentamicin 97.1 a a a
Tobramycin 97.1 a a a
Fluoroquinolones
Ciprofloxacin 100 a a a
Levofloxacin 100 a a a
Gatifloxacin 100 a a a
Garenoxacin 100 a a a
Others
Tetracycline 85.7 a a a
Trimethoprim/
sulfamethoxazole 100 a a a
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Serratia spp. Bacteremia Pneumonia Bacteremia Pneumonia
(32) (18) (22) (a)
Cephalosporins
Cefazolin     0   5.6   0 a
Cefuroxime     0     0   0 a
Cefoxitin     0   5.6   0 a
Ceftriaxone 62.5 83.3 68.2 a
Ceftazidime 78.1 94.4 77.3 a
Cefepime 68.8 94.4 77.3 a
Other β-lactams
Ampicillin   0   0  0 a
Aztreonam 68.8 88.9 77.3 a
Ticarcillin/clavulanate 34.4 72.2 31.8 a
Piperacillin/tazobactam 56.3 94.4 45.5 a
Imipenem 100 94.4 100 a
Meropenem 100 100 100 a
Aminoglycosides
Amikacin 62.5 83.3 59.1 a
Gentamicin 43.8 88.9 40.9 a
Tobramycin 37.5 72.2 31.8 a
Fluoroquinolones
Ciprofloxacin 56.3 100 45.5 a
Levofloxacin 62.5 100 50 a
Gatifloxacin 62.5 100 50 a
Garenoxacin 46.9 83.3 40.9 a
Others
Tetracycline   0   0   0 a
Trimethoprim/
sulfamethoxazole 46.9 83.3 45.5 a
Stenotrophomonas maltophilia Bacteremia Pneumonia Bacteremia Pneumonia
(38) (19) (16) (a)
Cephalosporins
Ceftazidime 65.8 52.6 93.8 a
Cefepime 39.5 26.3 62.5 a
Other β-lactams
Aztreonam  5.3   0   0 a
Ticarcillin/clavulanate 52.6 47.4 81.3 a
Piperacillin/tazobactam 29.7 15.8 43.8 a
Imipenem     0   0   0 a
Meropenem     2.6   5.3   6.3 a
Aminoglycosides
Amikacin 13.2 10.5 18.8 a
Gentamicin 10.5   0 18.8 a
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Tobramycin 10.5 5.3 18.8 a
Fluoroquinolones
Ciprofloxacin 68.4 42.1 62.5 a
Levofloxacin 100 100 100 a
Gatifloxacin 100 100 100 a
Garenoxacin 94.7 84.2 87.5 a
Others
Tetracycline 15.8 5.3 18.8 a
Trimethoprim/
sulfamethoxazole 97.4 100 100 a
a. The results were not analyzed because the number of isolates was low (<10);
b. Percentage of strains with MIC > 2 µg/mL, indicating possible ESBL production [6].
Table 5. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-positive pathogens
isolated in the year 2001 from patients with bacteremia and pneumonia
Pathogen/       % Susceptible strains (number of isolates tested)
Latin America Brazil
S. aureus Bacteremia Pneumonia Bacteremia Pneumonia
(389 (178) (182) (105)
Cephalosporins
Cefazolin 65b 43.3b 64.8b 47.6b
Ceftriaxone 65b 43.3b 64.8b 47.6b
Cefepime 65b 43.3b 64.8b 47.6b
Other β-lactams
Oxacillin 65 43.3 64.8 47.6
Penicillin 10 2.8 12.6 3.8
Amoxicillin/clavulanate 65b 43.3b 64.8b 47.6b
Piperacillin/tazobactam 65b 43.3b 64.8b 47.6b
Imipenem 65b 43.3b 64.8b 47.6b
MLS
Clindamycin 69.9 46.1 68.7 47.6
Erythromycin 57.6 39.9 54.9 40
Fluoroquinolones
Ciprofloxacin 66.6 47.2 68.1 49.5
Levofloxacin 71.2 51.1 73.1 54.3
Gatifloxacin 91.3 87.1 88.5 84.8
Garenoxacin 98.7 95.5 98.9 96.2
Others
Gentamicin 63.2 44.9 63.7 47.6
Rifampin 81.7 64 72.5 51.4
Chloramphenicol 78.7 65.7 74.7 62.9
Antimicrobial agents
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Tetracycline 81.2 62.9 67 51.4
Doxycycline 87.4 75.3 76.4 64.8
Trimethoprim/sulfamethoxale 79.7 64 62.1 52.4
Vancomycin 100 100 100 100
Teicoplanin 99.7 100 99.5 100
Quinupristin/dalfopristin 100 100 100 100
Linezolid 100 100 100 100
CoNS Bacteremia Pneumonia Bacteremia Pneumonia
(219) (11) (123) (11)
Cephalosporins
Cefazolin 19.6b 54.5b 15.4b 54.5b
Ceftriaxone 19.6b 54.5b 15.4b 54.5b
Cefepime 19.6b 54.5b 15.4b 54.5b
Other β-lactams
Oxacillin 19.6 54.5 15.4 54.5
Penicillin 10.5 36.4   8.9 36.4
Amoxicillin/clavulanate 19.6b 54.5b 15.4b 54.5b
Piperacillin/tazobactam 19.6b 54.5b 15.4b 54.5b
Imipenem 19.6b 54.5b 15.4b 54.5b
MLS
Clindamycin 55.7 63.6 49.6 63.6
Erythromycin 30.1 27.3 30.9 27.3
Fluoroquinolones
Ciprofloxacin 54.3 54.5 47.2 54.5
Gatifloxacin 93.2 81.8 92.7 81.8
Levofloxacin 65.3 54.5 61 54.5
Garenoxacin 95.4 90.9 95.1 90.9
Others
Gentamicin 45.9 54.5 40.2 54.5
Rifampin 77.2 72.7 74 72.7
Chloramphenicol 69.4 81.8 60.2 81.8
Tetracycline 78.1 63.6 74 63.6
Doxycycline 89 81.8 87.8 81.8
Trimethoprim/sulfamethoxale 51.1 27.3 39.8 27.3
Vancomycin 100 100 100 100
Teicoplanin 93.2 81.8 92.7 81.8
Quinupristin/dalfopristin 99.5 100 100 100
Linezolid 100 100 100 100
Enterococcus spp. Bacteremia Pneumonia Bacteremia Pneumonia
(64) (d) (28) (d)
β-lactams
  Ampicillin 90.6 d 96.4 d
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a. Interpreted by NCCLS 2003 criteria, when available [6]; b. Susceptibility is predicted by the oxacillin
result [6]; c. Susceptibility is predicted by the ampicillin result [6]; d. The results were not analyzed because
the number of isolates was low (<10).  Abbreviations: CoNS - coagulase negative staphylococci; HL - High
level aminoglycoside resistence screen; NA – Not applicable, there is no breakpoint established by the
NCCLS [6].
Penicillin 76.6 d 64.3 d
Amoxicillin/Clavulanate 90.6c d 96.4c d
Piperacillin/Tazobactam 90.6c d 96.4c d
MLS
Erythromycin   7.8 d 10.7 d
Fluoroquinolones
Ciprofloxacin 50 d 39.3 d
Levofloxacin 62.5 d 53.6 d
Gatifloxacin 60.9 d 53.6 d
Garenoxacin 90.6 d 89.3 d
Others
Gentamicin (HL) 60.9 d 46.4 d
Streptomycin (HL) 62.5 d 75 d
Rifampin 28.1 d 21.4 d
Chloramphenicol 62.5 d 46.4 d
Tetracycline 32.8 d 35.7 d
Doxycycline 42.2 d 39.3 d
Vancomycin 96.9 d 100 d
Teicoplanin 96.9 d 100 d
Quinupristin/dalfopristin 7.8 d 7.1 d
Linezolid 100 d 100 d
Table 6. Antimicrobial activity and spectrum of drugs tested against the five most prevalent Gram-negative
pathogens isolated from January 1997 to December 2001 throughout Latin America and in Brazil alone
Pathogen (no total/Brazil)/ Latin America Brazil
MIC50 MIC90 % Susceptible % Susceptible
Acinetobacter spp. (826/ 400)
Cephalosporins
Ceftazidime >16 >16 28.6 27.3
Cefepime 16 >16 35.4 33.8
Other β-lactams
Aztreonam >16 >16   7.6   6.5
Ticarcillin/clavulanate >128 >128 24.8 28.3
Piperacillin/tazobactam >64 >64 26.8 28.8
Imipenem 1 >8 86.9 90.8
Meropenem 1 >8 86.8 90.8
Antimicrobial agent
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Aminoglycosides
Amikacin >32 >32 34 32.3
Gentamicin >8 >16 32.9 37.8
Tobramycin 16 >16 41.7 51.8
Fluoroquinolones
Ciprofloxacin >2 >2 30.5 35.3
Levofloxacin >4 >4 32.3 36.3
Gatifloxacin 4 >4 34.4 38.5
Garenoxacin >4 >4 34.9 35.8
Others
Tetracycline <4 >8 51 56.1
Trimethoprim/
sulfamethoxazole >1 >2 32.4 31
Burkholderia cepacia (68/ 34)
Cephalosporins
Ceftazidime 4 16 82.4 85.3
Cefepime 8 >16 51.5 47.1
Other β-lactams
Aztreonam >16 >16 19.1 20.6
Ticarcillin/clavulanate >128 >128 17.6 14.7
Piperacillin/tazobactam 8 64 67.6 64.7
Imipenem 4 >8 52.9 52.9
Meropenem 2 >8 76.5 85.3
Aminoglycosides
Amikacin >32 >32 17.6   8.8
Gentamicin 16 >16 13.2   8.8
Tobramycin >16 >16 13.2   8.8
Fluoroquinolones
Ciprofloxacin 1 >2 60.3 70.6
Levofloxacin 1 4 80.9 82.4
Gatifloxacin 1 >4 77.9 79.4
Garenoxacin 2 >4 66.7 76.9
Others
Tetracycline >8 >8 13.2   8.8
Trimethoprim/
sulfamethoxazole < 0.5 >1 79.4 97.1
Citrobacter spp. (136/ 43)
Cephalosporins
Cefazolin >16 >16 19.1 18.6
Cefuroxime 8 >16 56.6 55.8
Cefoxitin >32 >32 20.6 20.9
Ceftriaxone 0.25 >32 70.6 65.1
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Ceftazidime 1 >16 67.6 62.8
Cefepime 0.12 4 93.4 95.3
Other β-lactams
Ampicillin >16 >16 12.5 11.6
Aztreonam 0.25 >16 66.2 60.5
Ticarcillin/clavulanate 4 >128 59.6 55.8
Piperacillin/tazobactam 4 >64 68.4 67.4
Imipenem 0.5 1 100 100
Meropenem 0.06 0.12 100 100
Aminoglycosides
Amikacin 2 32 81.6 74.4
Gentamicin <1 16 79.4 74.4
Tobramycin 1 >16 73.5 71.8
Fluoroquinolones
Ciprofloxacin 0.25 >2 81.6 76.7
Levofloxacin <0.5 4 84.6 81.4
Gatifloxacin 0.12 4 83.1 76.7
Garenoxacin 0.12 >4 85.3 81
Others
Tetracycline <4 >8 67.6 67.4
Trimethoprim/
sulfamethoxazole <0.5 >2 68.4 62.8
Enterobacter spp. (897/ 441)
Cephalosporins
Cefazolin >16 >16   5.1   3.9
Cefuroxime >16 >16 35.9 40.4
Cefoxitin >32 >32   2.2 5.9
Ceftriaxone 0.5 >32 64.2 69.4
Ceftazidime <1 >16 64 69.2
Cefepime <0.12 8 90.5 92.3
Other β-lactams
Ampicillin >16 >16   5.6   5.2
Aztreonam 0.25 >16 63.4 69.4
Ticarcillin/clavulanate 16 >128 52.1 55.8
Piperacillin/tazobactam 4 >64 64.9 68.3
Imipenem 0.5 1 99.8 99.5
Meropenem <0.06 0.25 99.7 99.5
Aminoglycosides
Amikacin 2 >32 83.4 82.3
Gentamicin <1 >8 74.1 74.6
Tobramycin 1 >16 63 66.8
Fluoroquinolones
Ciprofloxacin 0.25 >2 80.2 82.8
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Levofloxacin <0.5 >4 81.7 84.8
Gatifloxacin 0.06 >4 82.5 86.4
Garenoxacin 0.12 >4 75 85.6
Others
Tetracycline <4 >8 66.6 67.8
Trimethoprim/
sulfamethoxazole <0.5 >2 70.9 71.4
E. coli (3164/ 835)
Cephalosporins
Cefazolin <2 >16 81.8 86
Cefuroxime 4 16 88 89.1
Cefoxitin 4 8 92.8 93.8
Ceftriaxone <0.25 <0.25 94.6 (6.1)b 94.3 (6.7)b
Ceftazidime 0.25 <2 95.8 (6.5)b 95.3 (7.4)b
Cefepime <0.12 0.25 96.9 96.9
Other β-lactams
Ampicillin >16 >16 39.7 42.9
Aztreonam <0.12 0.25 94.7 (6.6)b 94.4 (7)b
Ticarcillin/clavulanate 8 128 65.2 72.7
Piperacillin/tazobactam 2 16 91.3 94.3
Imipenem 0.12 0.25 99.9 100
Meropenem <0.06 <0.06 99.9 100
Aminoglycosides
Amikacin 2 8 97.3 97.6
Gentamicin <1 8 89 92.5
Tobramycin 1 8 87 89.7
Fluoroquinolones
Ciprofloxacin 0.25 >2 82.9 89.7
Levofloxacin <0.5 >4 82.9 90.3
Gatifloxacin <0.03 >4 83.5 90.5
Garenoxacin 0.03 >4 84.4 91.2
Others
Tetracycline <4 >8 51.4 58.7
Trimethoprim/
sulfamethoxazole <0.5 >2 52.5 52.3
Haemophilus influenzae (1176/ 406)
Cephalosporins
Cefuroxime 1 2 98.6 97.8
Ceftriaxone 0.01 0.25 99.8 100
Ceftazidime 0.25 0.25 99.8 100
Cefepime 0.06 0.12 99.8 100
Other β-lactams
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Ampicillin < 0.5 >4 86.4c 87.4c
Aztreonam 0.12 0.12 100 100
Piperacillin/tazobactam < 0.5 < 0.5 99.3 100
Imipenem 0.25 0.5 100 100
Meropenem 0.06 0.06 100 100
Macrolides
Azithromycin 1 2 99.7 99.5
Clarithromycin 8 8 91.1 90.8
Fluoroquinolones
Ciprofloxacin 0.01 0.03 100 100
Gatifloxacin 0.03 0.03 100 100
Levofloxacin 0.03 < 0.5 100 100
Garenoxacin 0.03 0.03 100 100
Others
Tetracycline <2 <2 96.9 92.4
Choranphenicol <2 <2 97.5 96.4
Trimethoprim/
sulfamethoxazole < 0.5 >4 61 51.9
K. pneumoniae (1517/ 575)
Cephalosporins
Cefazolin 16 >16 49.6 46.3
Cefuroxime 8 >16 54 51.3
Cefoxitin 4 16 83.6 84.5
Ceftriaxone <0.25 >32 61.8 (42.5)b 57.9 (47.8)b
Ceftazidime <2 >16 66.8 (42.7)b 67.5 (48)b
Cefepime <0.12 >16 76.3 67.1
Other β-lactams
Ampicillin >16 >16     0   0
Aztreonam 0.25 >16 62.2 (41.7)b 57.7 (46.3)b
Ticarcillin/clavulanate 16 >128 50.4 49
Piperacillin/tazobactam 4 >64 66.8 68.5
Imipenem 0.25 0.5 99.8 100
Meropenem <0.06 0.12 99.4 99.5
Aminoglycosides
Amikacin 2 32 80.7 81.6
Gentamicin <1 >16 65.1 63.1
Tobramycin 1 >16 53.9 51.3
Fluoroquinolones
Ciprofloxacin 0.25 >2 86.5 88.9
Levofloxacin <0.5 4 88.7 89.6
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Gatifloxacin 0.06 2 89.8 90.3
Garenoxacin 0.12 >4 87.1 85.6
Others
Tetracycline <4 >8 65.6 69.7
Choranphenicol <2 <2 99.7 99.3
Trimethoprim/
sulfamethoxazole <0.5 2 68.2 62.1
Moraxella catarrhalis (379/141)
Beta-lactams
Ampicillin < 2 4   4.5c   5c
Cefuroxime 1 2 99.5 100
Ceftriaxone 0.25 0.5 100 100
Ceftazidime 0.25 0.25 99.6 100
Cefepime 0.5 2 98.2 97.2
Macrolides
Azithromycin <0.12 <0.12 100 100
Clarithromycin <0.25 <0.25 100 100
Fluoroquinolones
Ciprofloxacin 0.03 0.06 100 100
Levofloxacin 0.03 < 0.5 100 100
Gatifloxacin 0.03 0.06 100 100
Garenoxacin 0.03 0.03 100 100
Others
Tetracycline < 2 < 2 92.9 100
Trimethoprim/
sulfamethoxazole < 0.5 1 89.1 86.5
Morganella morgannii (80/ 29)
Cephalosporins
Cefazolin >16 >16   3.8   6.9
Cefuroxime >16 >16 10 10.3
Cefoxitin 16 >32 43.8 37.9
Ceftriaxone 0.25 4 92.5 82.8
Ceftazidime 0.25 8 90 93.1
Cefepime 0.12 2 95 89.7
Other β-lactams
Ampicillin >16 >16   0   0
Aztreonam 0.12 16 87.5 82.8
Ticarcillin/clavulanate 4 64 82.5 86.2
Piperacillin/tazobactam <0.5 8 92.5 96.6
Imipenem 2 4 97.5 93.1
Meropenem 0.06 0.25 100 100
Aminoglycosides
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Fluoroquinolones
Ciprofloxacin 0.25 >2 76.3 69
Levofloxacin <0.5 >4 76.3 72.4
Gatifloxacin 0.12 >4 76.3 69
Garenoxacin 0.5 >4 71.1 40
Others
Tetracycline <4 >8 51.3 37.9
Trimethoprim/
sulfamethoxazole <0.5 >2 67.5 58.6
P. aeruginosa (1984/ 913)
Cephalosporins
Ceftazidime 4 >16 62.4 56
Cefepime 8 >16 62.7 53.9
Other β-lactams
Aztreonam 16 >16 44.5 38.2
Ticarcillin/clavulanate 64 >128 55.6 47.8
Piperacillin/tazobactam 16 >64 72.1 64.6
Imipenem 2 >8 71.9 62.5
Meropenem 1 >8 74.8 65.8
Aminoglycosides
Amikacin 4 >32 70 58.4
Gentamicin 4 >16 58.2 49.7
Tobramycin 1 >16 58.2 47.9
Fluoroquinolones
Ciprofloxacin 0.5 >2 58.1 52.8
Levofloxacin 1 >4 56.8 52.4
Gatifloxacin 2 >4 54.4 50.2
Garenoxacin 4 >4 46.3 42
Others
Tetracycline >8 >8   1.5   0.9
Trimethoprim/
sulfamethoxazole >2 >2   3.4   3.8
Proteus spp (328/ 66)
Cephalosporins
Cefazolin 4 >16 62.2 74.2
Cefuroxime 2 >16 69.8 78.8
Cefoxitin 4 8 93.9 95.5
Ceftriaxone 0.25 >32 81.4 92.4
Ceftazidime 0.12 2 96.3 98.5
Cefepime 0.12 >16 83.2 92.4
Other β-lactams
Ampicillin 4 >16 52.4 56.1
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Aztreonam 0.12 4 93.6 95.5
Ticarcillin/clavulanate <1 16 94.5 97
Piperacillin/tazobactam <0.5 2 94.2 98.5
Imipenem 1 4 98.8 98.5
Meropenem 0.06 0.25 100 100
Aminoglycosides
Amikacin 4 16 93.6 97
Gentamicin 1 >16 74.4 87.9
Tobramycin 2 16 75.6 87.7
Fluoroquinolones
Ciprofloxacin 0.25 >2 76.2 92.4
Levofloxacin <0.5 >4 79.6 95.5
Gatifloxacin 0.12 >4 76.8 93.9
Garenoxacin 0.5 >4 75.1 87.8
Others
Tetracycline >8 >8   5.5 9.1
Trimethoprim/
sulfamethoxazole <0.5 >2 61.6 71.2
Salmonella spp (308/ 97)
Cephalosporins
Cefazolin <2 4 96.8 99
Cefuroxime 4 8 96.8 96.9
Cefoxitin 2 4 97.7 97.9
Ceftriaxone 0.25 0.25 100 100
Ceftazidime <1 <2 100 100
Cefepime 0.12 0.12 100 100
Other β-lactams
Ampicillin <2 16 89.3 96.9
Aztreonam 0.12 0.12 99 100
Ticarcillin/clavulanate 2 8 92.5 100
Piperacillin/tazobactam 2 4 99.4 100
Imipenem 0.25 0.25 100 100
Meropenem 0.06 0.06 100 100
Aminoglycosides
Amikacin 1 4 99.7 100
Gentamicin <1 1 96.4 95.8
Tobramycin 1 2 95.7 94.3
Fluoroquinolones
Ciprofloxacin 0.01 0.25 100 100
Levofloxacin 0.06 <0.5 100 100
Gatifloxacin 0.03 0.12 100 100
Garenoxacin 0.06 0.12 100 100
Others
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Tetracycline <4 8 86.4 94.8
Trimethoprim/
sulfamethoxazole <0.5 <0.5 93.8 97.9
Serratia spp. (320/ 169)
Cephalosporins
Cefazolin >16 >16   1.6   1.2
Cefuroxime >16 >16   2.2   0.6
Cefoxitin 32 >32   8.1   6.5
Ceftriaxone 0.5 >32 76.3 71.6
Ceftazidime 0.5 >16 86.3 81.1
Cefepime 0.25 16 89.4 93.5
Other β-lactams
Ampicillin >16 >16   4.1  3
Aztreonam 0.25 >16 82.8 84
Ticarcillin/clavulanate 16 >128 57.8 47.9
Piperacillin/tazobactam 2 >64 73.1 64.5
Imipenem 1 2 99.7 100
Meropenem 0.06 0.25 100 100
Aminoglycosides
Amikacin 4 >32 73.4 66.9
Gentamicin 1 >16 66.6 56.2
Tobramycin 4 >16 54.4 45
Fluoroquinolones
Ciprofloxacin 0.25 >2 74.1 59.8
Levofloxacin <0.5 4 82.2 69.8
Gatifloxacin 0.25 >4 80 67.5
Garenoxacin 2 >4 62.5 51.7
Others
Tetracycline >8 >8 7.5   4.7
Trimethoprim/
sulfamethoxazole <0.5 >2 66.9 58.6
Shigella spp (209/ 87)
Cephalosporins
Cefazolin <2 4 98.6 98.9
Cefuroxime 2 4 99 98.9
Cefoxitin 2 4 99 98.9
Ceftriaxone 0.25 0.25 99.5 100
Ceftazidime < 2 < 2 100 100
Cefepime 0.12 0.25 100 100
Other β-lactams
Ampicillin >16 >16 30.1 31
Aztreonam 0.12 0.12 99 98.9
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a.  The results were not analyzed because the number of isolates was low (<10); b.  Percentage of strains with
MIC > 2 µg/mL, indicating possible ESBL production [6]; c. Percentage of non-beta-lactamase producing
strains. This value also represents the susceptbility rate to amoxicillin [6].
Ticarcillin/clavulanate 16 32 82.8 86.2
Piperacillin/tazobactam 2 2 99 100
Imipenem 0.12 0.25 100 100
Meropenem 0.06 0.06 100 100
Aminoglycosides
Amikacin 8 8 100 100
Gentamicin <1 2 100 100
Tobramycin 1 2 100 100
Fluoroquinolones
Ciprofloxacin 0.01 0.01 100 100
Levofloxacin 0.03 0.03 100 100
Gatifloxacin 0.03 0.03 100 100
Garenoxacin 0.03 0.03 100 100
Others
Tetracycline <4 > 8 53.1 71.3
Trimethoprim/
sulfamethoxazole >2 > 2 25.8 14.9
Stenotrophomonas maltophilia (166/ 62)
Cephalosporins
Ceftazidime 8 >16 57.8 66.1
Cefepime 16 >16 31.3 35.5
Other β-lactams
Aztreonam >16 >16   5.4 4.8
Ticarcillin/clavulanate 16 128 56 69.4
Piperacillin/tazobactam 64 >64 33.3 40.3
Imipenem >8 >8   1.2   0
Meropenem >8 >8   4.8   6.5
Aminoglycosides
Amikacin >32 >32 16.3 12.9
Gentamicin >8 >16 15.1 11.3
Tobramycin >16 >16 13.1   8.1
Fluoroquinolones
Ciprofloxacin 2 >2 43.4 33.9
Levofloxacin 0.5 4 88 90.3
Gatifloxacin 0.5 2 91 93.5
Garenoxacin 1 4 82.4 78.4
Others
Tetracycline >8 >8 14.5 12.9
Trimethoprim/
sulfamethoxazole <0.5 <0.5 97.1 100
56 BJID 2004; 8 (February)
www.bjid.com.br
Antimicrobial Surveillance Program Report: Latin American and Brazil
Table 7. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-positive cocci
isolated from January 1997 to December 2001 throughout Latin America and in Brazil alone
Pathogen (no total/Brazil)/ Latin America Brazil
MIC50 MIC90 % Susceptible % Susceptible
S. aureus (3396/ 1516)
Cephalosporins
Cefazolin <2 >16 63.2b 62.7b
Ceftriaxone 4 >32 63.2b 62.7b
Cefepime 8 >16 63.2b 62.7b
Other β-lactams
Oxacillin 0.5 >8 63.2 62.7
Penicillin 16 >32   7.2   9
Amoxicillin/clavulanate 2 >16 63.2 b 62.7b
Piperacillin/tazobactam 2 >64 63.2 b 62.7b
Imipenem <0.06 >8 63.2b 62.7b
MLS
Clindamycin 0.25 >8 66 64.1
Erythromycin 0.5 >8 50.5 47.9
Fluoroquinolones
Ciprofloxacin 0.5 >2 64.5 63.4
Levofloxacin 0.25 4 66.3 64.8
Gatifloxacin 0.12 4 89.6 87.8
Garenoxacin 0.03 2 97.6 96.9
Others
Gentamicin <1 >16 62.7 61.9
Rifampin <0.25 2 76.6 67.8
Chloramphenicol 8 >16 64.4 63.2
Tetracycline <4 >8 71.1 60.9
Doxycycline <0.5 >4 83.7 75.2
Trimethoprim/sulfamethoxale <0.5 >1 75.8 63.5
Vancomycin 1 1 100 100
Teicoplanin 1 2 99.6 99.6
Quinupristin/dalfopristin 0.25 0.5 99.7 99.9
Linezolid 2 4 100 100
CoNS (1397/ 514)
Cephalosporins
Cefazolin <2 >16 22.8b 19.5b
Ceftriaxone 16 >32 22.8b 19.5b
Cefepime 16 >16 22.8b 19.5b
Other β-lactams
Oxacillin 8 >8 22.8 19.5
Antimicrobial agent
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Penicillin 8 >32   9.3   8.2
Amoxicillin/clavulanate <2 >16 22.8b 19.5b
Piperacillin/tazobactam 2 >64 22.8b 19.5b
Imipenem 0.5 >8 22.8b 19.5b
MLS
Clindamycin 0.25 >8 55.3 46.3
Erythromycin >8 >8 35.3 34.6
Fluoroquinolones
Ciprofloxacin 0.5 >2 56.9 47.9
Levofloxacin 0.25 >4 65.7 58.1
Gatifloxacin 0.12 2 93.8 92.8
Garenoxacin 0.03 2 91.5 92.4
Others
Gentamicin 8 >16 45.1 40.5
Rifampin 0.25 >2 72 68.1
Chloramphenicol 8 >16 62.7 55.6
Tetracycline <4 >8 76.5 74.9
Doxycycline 1 >4 87.1 85.8
Trimetoprim/sulfametoxale 1 >2 50.6 38.4
Vancomycin 2 2 100 100
Teicoplanin 2 8 90.3 90.3
Quinupristin/dalfopristin 0.25 0.5 98.7 98.2
Linezolid 1 2 100 100
Enterococcus spp. (583/ 243)
β-lactams
Ampicillin 1 4 94.7 97.5
Penicillin 2 16 90.2 81.5
Amoxicillin/Clavulanate <2 4 94.7c 97.5c
Piperacillin/Tazobactam 4 >64 94.7c 97.5c
MLS
Erythromycin >8 >8 9.4 9.1
Fluoroquinolones
Ciprofloxacin 1 >2 52.7 46.9
Levofloxacin 1 >4 65.7 56.3
Gatifloxacin 0.5 >4 73.9 66.7
Garenoxacin 0.25 4 93.6 94.9
Others
Gentamicin (HL) <500 >1,000 76.2 65
Streptomycin (HL) <1,000 <1,000 90.1 94.7
Rifampin >2 >2 23.3 18.1
Chloramphenicol 8 >16 67.2 55.6
Tetracycline >8 >8 33.4 32.1
Doxycycline >4 >4 44.4 49.4
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Table 8. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-negative pathogens
isolated from January 1997 to December 2001 throughout Latin America and in Brazil alone, from patients with
bacteremia and pneumonia
Pathogen/      % Susceptible strainsa (number of isolates tested)
          Latin America Brazil
Acinetobacter spp. Bacteremia Pneumonia Bacteremia Pneumonia
(380) (299) (212) (139)
Cephalosporins
Ceftazidime 40 17.7 40.6 12.2
Cefepime 46.1 25.8 45.8 19.4
Other β-lactams
Aztreonam 11.8   4.3 10.8 2.2
Ticarcillin/clavulanate 35.8 13.4 40.1 12.9
Piperacillin/tazobactam 37.6 16.4 39.6 15.1
Imipenem 88.9 85.3 91.5 89.2
Meropenem 89.5 84.3 92.5 88.5
Aminoglycosides
Amikacin 43.2 23.1 43.9 17.3
Gentamicin 44.2 23.4 49.5 23.7
Tobramycin 52.4 32.7 64.7 36.2
Fluoroquinolones
Ciprofloxacin 42.9 18.7 46.7 20.1
Levofloxacin 45 21.1 48.6 20.1
Gatifloxacin 45.5 24.1 48.6 25.2
Garenoxacin 48.9 24.5 48.7 19.7
Others
Tetracycline 59.9 46.2 65.9 46
Trimethoprim/
sulfamethoxazole 42.4 23.4 40.6 19.4
Burkholderia cepacia Bacteremia Pneumonia Bacteremia Pneumonia
(43) (19) (21) (b)
Cephalosporins
Ceftazidime 79.1 84.2 85.7 b
Cefepime 48.8 57.9 33.3 b
a. Interpreted by NCCLS 2003 criteria, when available [6]; b. Susceptibility is predicted by the oxacillin
result [6]; c. Susceptibility is predicted by the ampicillin result [6]; Abbreviations: HL - High level
aminoglycoside resistance screen.
Vancomycin 1 2 97.5 97.5
Teicoplanin 0.25 0.5 98.1 97.5
Linezolid 2 2 96.4 97
Antimicrobial agent
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Other β-lactams
Aztreonam 16.3 15.8 19 b
Ticarcillin/clavulanate 14 26.3 9.5 b
Piperacillin/tazobactam 62.8 84.2 52.4 b
Imipenem 48.8 57.9 38.1 b
Meropenem 79.1 68.4 85.7 b
Aminoglycosides
Amikacin 16.3 21.1 4.8 b
Gentamicin 7 26.3 4.8 b
Tobramycin 9.3 21.1 4.8 b
Fluoroquinolones
Ciprofloxacin 65.1 47.4 71.4 b
Gatifloxacin 76.7 78.9 76.2 b
Levofloxacin 81.4 84.2 81 b
Garenoxacin 62.5 75 66.7 b
Others
Tetracycline 9.3 26.3 4.8 b
Trimethoprim/
sulfamethoxazole 74.4 89.5 95.2 b
Citrobacter spp. Bacteremia Pneumonia Bacteremia Pneumonia
(51) (24) (16) (b)
Cephalosporins
Cefazolin 15.7 33.3 12.5 b
Cefuroxime 51 54.2 50 b
Cefoxitin 15.7 33.3 12.5 b
Ceftriaxone 62.7 66.7 56.3 b
Ceftazidime 60.8 66.7 56.3 b
Cefepime 92.2 91.7 87.5 b
Other β-lactams
Ampicillin 17.6 12.5 12.5 b
Aztreonam 56.9 66.7 50 b
Ticarcillin/clavulanate 52.9 62.5 37.5 b
Piperacillin/tazobactam 66.7 75 62.5 b
Imipenem 100 100 100 b
Meropenem 100 100 100 b
Aminoglycosides
Amikacin 84.3 79.2 75 b
Gentamicin 78.4 83.3 62.5 b
Tobramycin 72.3 73.7 62.5 b
Fluoroquinolones
Ciprofloxacin 82.4 83.3 75 b
Levofloxacin 82.4 95.8 75 b
Gatifloxacin 80.4 95.8 75 b
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Garenoxacin 83.3 100 87.5 b
Others
Tetracycline 74.5 70.8 75 b
Trimethoprim/
sulfamethoxazole 64.7 70.8 56.3 b
Enterobacter spp. Bacteremia Pneumonia Bacteremia Pneumonia
(517) (165) (266) (76)
Cephalosporins
Cefazolin   5.2   6.1   4.1  6.6
Cefuroxime 37.7 40.6 44.7 43.4
Cefoxitin   5.2 5.5   6  9.2
Ceftriaxone 67.1 61.2 74.4 61.8
Ceftazidime 66.9 63 73.3 63.2
Cefepime 90.3 90.3 92.1 90.8
Other β-lactams
Ampicillin   5.4   6.7   5.3  7.9
Aztreonam 67.1 62.4 74.8 64.5
Ticarcillin/clavulanate 55.3 52.7 61.7 51.3
Piperacillin/tazobactam 67.9 64.8 72.9 65.8
Imipenem 99.8 99.4 99.6 98.7
Meropenem 99.8 98.8 99.6 98.7
Aminoglycosides
Amikacin 82.6 86.7 83.1 86.8
Gentamicin 74.5 79.4 76.7 78.9
Tobramycin 63.8 68.3 69.6 69
Fluoroquinolones
Ciprofloxacin 83.2 81.2 85.7 86.8
Levofloxacin 84.5 83 87.6 89.5
Gatifloxacin 85.3 83.6 89.5 89.5
Garenoxacin 77.8 78.5 84.4 93.8
Others
Tetracycline 68.3 73.3 71.1 71.1
Trimethoprim/
sulfamethoxazole 70.7 77.9 72.5 76
E. coli Bacteremia Pneumonia Bacteremia Pneumonia
(1620) (128) (419) (46)
Cephalosporins
Cefazolin 83.8 56.3 86.4 63
Cefuroxime 88.5 68 89.5 69.6
Cefoxitin 92.4 84.4 93.8 95.7
Ceftriaxone 94.7 (6.1)a 78.9 (21.1)a 94.5( 6)a 76.1 (19.6)a
Ceftazidime 95.7 (6.4)a 89.1 (21.9)a 95 (6.4)a 89.1 (19.6)a
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Cefepime 97.2 85.9 97.1 87
Other β-lactams
Ampicillin 39.8 28.9 42.2 26.1
Aztreonam 94.9 (6.2)a 78.7 (21.3)a 94.7 (5.7)a 80 (20)a
Ticarcillin/clavulanate 66.7 48.4 72.8 58.7
Piperacillin/tazobactam 92.5 77.3 93.6 82.6
Imipenem 100 99.2 100 100
Meropenem 100 100 100 100
Aminoglycosides
Amikacin 97 92.2 97.6 97.8
Gentamicin 90.4 77.3 93.3 82.6
Tobramycin 88.7 72 91.5 73.3
Fluoroquinolones
Ciprofloxacin 85.5 78.1 92.4 91.3
Gatifloxacin 86.2 78.9 93.3 91.3
Levofloxacin 86.1 78.1 93.3 91.3
Garenoxacin 85.9 73.2 92.4 89.3
Others
Tetracycline 53.7 54.7 60.9 65.2
Trimethoprim/
sulfamethoxazole 50.9 58.3 47.5 63
K. pneumoniae Bacteremia Pneumonia Bacteremia Pneumonia
(840) (328) (328) (124)
Cephalosporins
Cefazolin 47.5 54.6 47.3 45.2
Cefuroxime 52.7 55.2 53.7 46
Cefoxitin 84.6 82 86.6 83.9
Ceftriaxone 60.7 (45)b 63.1 (41.2)b 59.8 (45.4)b 50.8 (51.6)a
Ceftazidime 65.2 (45)b 67.4 (39.3)b 70.1 (43.9)b 57.3 (60)b
Cefepime 75.7 77.4 73.8 72.6
Other β-lactams
Ampicillin   0   0   0   0
Aztreonam 60.2 (44)b 63.4 (40.2)b 60.4 (43.6)b 51.6 (60)b
Ticarcillin/clavulanate 48.9 56.7 50.9 46.8
Piperacillin/tazobactam 65.4 72.3 69.8 66.9
Imipenem 99.9 99.7 100 100
Meropenem 99.8 99.4 99.7 99.2
Aminoglycosides
Amikacin 78.6 85.7 80.8 85.5
Gentamicin 62.5 71.6 63.1 66.9
Tobramycin 50.6 60.6 52.3 52.7
Fluoroquinolones
Ciprofloxacin 88.1 87.5 91.8 88.7
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Levofloxacin 90.1 88.4 91.8 88.7
Gatifloxacin 91.2 89.9 93 88.7
Garenoxacin 89.1 88.5 89.6 86.7
Others
Tetracycline 65.3 71.6 72.9 66.1
Trimethoprim/
sulfamethoxazole 66.1 76.1 59.3 66.1
Morganella morgannii Bacteremia Pneumonia Bacteremia Pneumonia
(32) (b) (12) (b)
Cephalosporins
Cefazolin   0 b   0 b
Cefuroxime   6.3 b   8.3 b
Cefoxitin 31.3 b 33.3 b
Ceftriaxone 87.5 b 75 b
Ceftazidime 84.4 b 91.7 b
Cefepime 90.6 b 83.3 b
Other β-lactams
Ampicillin   0 b   0 b
Aztreonam 84.4 b 83.3 b
Ticarcillin/clavulanate 71.9 b 83.3 b
Piperacillin/tazobactam 90.6 b 100 b
Imipenem 100 b 100 b
Meropenem 100 b 100 b
Aminoglycosides
Amikacin 96.9 b 91.7 b
Gentamicin 81.3 b 91.7 b
Tobramycin 85.7 b 81.8 b
Fluoroquinolones
Ciprofloxacin 68.8 b 66.7 b
Levofloxacin 68.8 b 66.7 b
Gatifloxacin 68.8 b 66.7 b
Garenoxacin 66.7 b       b b
Others
Tetracycline 40.6 b 25 b
Trimethoprim/
sulfamethoxazole 56.3 b 50 b
P. aeruginosa Bacteremia Pneumonia Bacteremia Pneumonia
(589) (862) (247) (473)
Cephalosporins
Ceftazidime 69.1 58.7 66.8 51.8
Cefepime 71 58.5 65.2 51.2
Other β-lactams
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Aztreonam 51.3 42.1 49.8 35.1
Ticarcillin/clavulanate 62.8 52.8 18.2 13.1
Piperacillin/tazobactam 78.9 67.1 59.1 44
Imipenem 83.4 65.5 79.8 56.4
Meropenem 84.6 68.3 80.6 59.6
Aminoglycosides
Amikacin 75.4 68.7 69.2 57.3
Gentamicin 65.5 56.3 63.2 47.8
Tobramycin 64.8 57.7 59 47.9
Fluoroquinolones
Ciprofloxacin 66.2 55.7 66.4 50.7
Levofloxacin 65.7 54.4 66.8 50.5
Gatifloxacin 63.7 50.9 64.8 47.4
Garenoxacin 57.7 40.7 58.9 39
Others
Tetracycline   1.5   1.5   1.6 0.8
Trimethoprim/
sulfamethoxazole   2.2   5.2   3.6 5.1
Proteus spp. Bacteremia Pneumonia Bacteremia Pneumonia
(92) (42) (15) (b)
Cephalosporins
Cefazolin 54.3 54.8 80 b
Cefuroxime 65.2 59.5 86.7 b
Cefoxitin 95.7 90.5 100 b
Ceftriaxone 72.8 66.7 100 b
Ceftazidime 93.5 97.6 100 b
Cefepime 75 66.7 100 b
Other β-lactams
Ampicillin 43.5 57.1 60 b
Aztreonam 92.4 83.3 100 b
Ticarcillin/clavulanate 90.2 97.6 100 b
Piperacillin/tazobactam 91.3 92.9 100 b
Imipenem 97.8 100 93.3 b
Meropenem 100 100 100 b
Aminoglycosides
Amikacin 91.3 88.1 100 b
Gentamicin 63 69 100 b
Tobramycin 65.4 69.4 100 b
Fluoroquinolones
Ciprofloxacin 68.5 71.4 100 b
Levofloxacin 70.7 76.2 100 b
Gatifloxacin 67.4 71.4 100 b
Garenoxacin 70.2 72 b b
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Others
Tetracycline   4.3   7.1 13.3 b
Trimethoprim/
sulfamethoxazole 53.3 64.3 86.7 b
Salmonella spp. Bacteremia Pneumonia Bacteremia Pneumonia
(179) (b) (44) (b)
Cephalosporins
Cefazolin 97.8 b 100 b
Cefuroxime 95.5 b 95.5 b
Cefoxitin 98.3 b 97.7 b
Ceftriaxone 98.9 b 100 b
Ceftazidime 98.9 b 100 b
Cefepime 98.9 b 100 b
Other β-lactams
Ampicillin 92.2 b 100 b
Aztreonam 98.3 b 100 b
Ticarcillin/clavulanate 93.3 b 100 b
Piperacillin/tazobactam 98.9 b 100 b
Imipenem 100 b 100 b
Meropenem 100 b 100 b
Aminoglycosides
Amikacin 99.4 b 100 b
Gentamicin 96.1 b 95.5 b
Tobramycin 94.7 b 91.7 b
Fluoroquinolones
Ciprofloxacin 100 b 100 b
Levofloxacin 100 b 100 b
Gatifloxacin 100 b 100 b
Garenoxacin 100 b 100 b
Others
Tetracycline 87.2 b 97.7 b
Trimethoprim/
sulfamethoxazole 93.3 b 100 b
Serratia spp. Bacteremia Pneumonia Bacteremia Pneumonia
(157) (89) (86) (40)
Cephalosporins
Cefazolin   0   2.2   0   0
Cefuroxime   1.3   3.4   0   0
Cefoxitin   8.3   3.4   5.8   2.5
Ceftriaxone 72.6 80.9 69.8 72.5
Ceftazidime 85.4 85.4 81.4 77.5
Cefepime 86 93.3 90.7 97.5
Other β-lactams
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Ampicillin   4.5   1.1 2.3     0
Aztreonam 79.6 88.8 82.6 87.5
Ticarcillin/clavulanate 57.3 60.7 48.8 45
Piperacillin/tazobactam 72 77.5 62.8 70
Imipenem 100 98.9 100 100
Meropenem 100 100 100 100
Aminoglycosides
Amikacin 70.7 80.9 64 75
Gentamicin 63.7 75.3 53.5 62.5
Tobramycin 51.8 57.9 42.9 45.9
Fluoroquinolones
Ciprofloxacin 75.2 78.7 60.5 67.5
Levofloxacin 82.2 87.6 69.8 77.5
Gatifloxacin 79.6 84.3 65.1 75
Garenoxacin 59.2 75 46.5 63.2
Others
Tetracycline   9.6   7.9   4.7   5
Trimethoprim/
sulfamethoxazole 63.1 70.8 54.7 60
Stenotrophomonas maltophilia Bacteremia Pneumonia Bacteremia Pneumonia
(86) (60) (35) (23)
Cephalosporins
Ceftazidime 73.3 46.7 85.7 47.8
Cefepime 40.7 23.3 42.9 30.4
Other β-lactams
Aztreonam 8.1   1.7   8.6   0
Ticarcillin/clavulanate 64 51.7 77.1 69.6
Piperacillin/tazobactam 43.5 26.7 51.4 30.4
Imipenem 2.3   0     0   0
Meropenem 7   3.3 5.7   8.7
Aminoglycosides
Amikacin 20.9 15 17.1   8.7
Gentamicin 20.9 11.7 14.3   8.7
Tobramycin 19   8.9 8.6   8.7
Fluoroquinolones
Ciprofloxacin 50 38.3 45.7 17.4
Levofloxacin 88.4 90 94.3 87
Gatifloxacin 88.4 96.7 94.3 95.7
Garenoxacin 83.3 81.8 79.2 80
Others
Tetracycline 17.4 13.3 17.1   8.7
Trimethoprim/
sulfamethoxazole 95.3 100 100 100
a. Percentage of strains with MIC > 2 µg/mL, indicating possible ESBL production [6]; b. The results were not
analyzed because the number of isolates was low (<10).
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Table 9. Antimicrobial activity and spectrum of drugs tested against the most prevalent Gram-positive pathogens
isolated from January 1997 to December 2001 throughout Latin America and in Brazil alone, from patients with
bacteremia and pneumonia
Pathogen/ % Susceptible strains (number of isolates tested)
Latin America Brazil
S. aureus Bacteremia Pneumonia Bacteremia Pneumonia
(1,921) (760) (840) (346)
Cephalosporins
Cefazolin 68.5a 45.4a 68.2a 48.8a
Ceftriaxone 68.5a 45.4a 68.2a 48.8a
Cefepime 68.5a 45.4a 68.2a 48.8a
Other β-lactams
Oxacillin 68.5 45.4 68.2 48.8
Penicillin   8.5   5.7 11.2   6.4
Amoxicillin/clavulanate 68.5a 45.4a 68.2a 48.8a
Piperacillin/tazobactam 68.5a 45.4a 68.2a 48.8a
Imipenem 68.5a 45.4a 68.2a 48.8a
MLS
Clindamycin 72 46.3 69.9 48.6
Erythromycin 54.6 37.4 52.5 38.4
Fluoroquinolones
Ciprofloxacin 70.3 45.9 69.5 48
Levofloxacin 72.9 48.4 72.2 50.3
Gatifloxacin 90.7 85.7 88.3 85.3
Garenoxacin 97.9 95.4 97.1 95.1
Others
Gentamicin 67.4 45.8 66.8 49.1
Rifampin 80.4 66.3 74.8 53.8
Chloramphenicol 68 54.5 68.6 54.3
Tetracycline 75 61.6 66.3 48.6
Doxycycline 87 75.7 80.1 64.7
Trimetoprim/sulfametoxale 79.4 64.8 87 74.8
Vancomycin 100 100 100 100
Teicoplanin 99.5 99.9 99.3 100
Quinupristin/dalfopristin 99.6 100 99.8 100
Linezolid 100 100 100 100
CoNS Bacteremia Pneumonia Bacteremia Pneumonia
(1,221) (41) (458) (19)
Cephalosporins
Cefazolin 23.8a 24.4a 19.2a 36.8a
Ceftriaxone 23.8a 24.4a 19.2a 36.8a
Antimicrobial agent
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Cefepime 23.8a 24.4a 19.2a 36.8a
Other β-lactams
Oxacillin 23.8 24.4 19.2 36.8
Penicillin   9.3 12.2   7.9 21.1
Amoxicillin/clavulanate 23.8a 24.4a 19.2a 36.8a
Piperacillin/tazobactam 23.8a 24.4a 19.2a 36.8a
Imipenem 23.8a 24.4a 19.2a 36.8a
MLS
Clindamycin 55.8 36.6 46.3 47.4
Erythromycin 36 17.1 35.4 26.3
Fluoroquinolones
Ciprofloxacin 58 31.7 48.5 42.1
Levofloxacin 66.2 57.9 59.9 53.3
Gatifloxacin 94.6 80.5 93 84.2
Garenoxacin 97.9 67.9 92.6 87.5
Others
Gentamicin 44.8 36.6 40 42.1
Rifampin 72.5 68.3 69 63.2
Chloramphenicol 62.2 63.4 55.2 68.4
Tetracycline 77.1 75.6 75.8 57.9
Doxycycline 87.7 82.9 86.7 68.4
Trimethoprim/sulfamethoxale 51.1 70.7 69.8 68.4
Vancomycin 100 100 100 100
Teicoplanin 90.6 85.4 90.4 89.5
Quinupristin/dalfopristin 98.6 100 98 100
Linezolid 100 100 100 100
Enterococcus spp. Bacteremia Pneumonia Bacteremia Pneumonia
(280) (58) (101) (44)
β-lactams
Ampicillin 91.8 100 95 100
Penicillin 84.6 81 78.2 75
Amoxicillin/Clavulanate 91.8b 100b 95b 100b
Piperacillin/Tazobactam 91.8b 100b 95b 100b
MLS
Erythromycin   9.3 13.8   5 15.9
Fluoroquinolones
Ciprofloxacin 48.2 48.3 40.6 43.2
Levofloxacin 67.2 41.2 57.4 36.4
Gatifloxacin 72.1 63.8 62.4 63.6
Garenoxacin 90 91.2 90.6 91.3
Others
Gentamicin (HL) 73.9 65.5 57.4 65.9
Streptomycin (HL) 88.2 91.4 92.1 95.5
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Table 10. Antimicrobial activity and spectrum of drugs tested against the most prevalent streptococci isolated
from January 1997 to December 2001 throughout Latin America and in Brazil alone
Pathogen (no total/Brazil)/ Latin Americaa Brazila
MIC50 MIC90 % susceptible % susceptible
β-haemolytic streptococci
(443/178)
Amoxicillin 0.06 0.12 100d 100d
Penicillin 0.03 0.06 100 100
Cefuroximeb 0.06 0.12 100d 100d
Cefprozil <0.12 0.5 100d 100d
Cefpodoxime 0.06 0.12 100d 100d
Cefotaximec 0.06 0.12 100 100
Cefepime 0.12 0.12 100 100
Erythromycin 0.06 0.25 92.8 96.6
Azithromycin 0.06 0.12 92.2 95
Clarithromycin 0.25 0.25 96.1 94.1
Clindamycin 0.06 0.12 97.7 99.4
Levofloxacin 0.5 1 100 100
Gatifloxacin 0.25 0.5 100 100
Garenoxacin 0.06 0.12 —- —-
Chloramphenicol <2 4 98.4 100
Tetracyclinee 4 >8 49.9 38.8
Trimethoprim/sulfamethoxale <0.5 <0.5 NA NA
Linezolid 1 1 100 100
Quinupristin/ dalfopristin 0.25 0.5 100 100
Vancomycin 0.5 0.5 100 100
S. bovis (29/18)
Amoxicillin 0.06 0.12 100d 94.4d
a. Interpreted by NCCLS 2003 criteria, when available [6]; b. Susceptibility is predicted by the oxacillin
result [6]; c. Susceptibility is predicted by the ampicillin result [6]. Abbreviation: HL - High level
aminoglycoside resistance screen.
Rifampin 25.4 20.7 19.8 11.4
Chloramphenicol 66.4 55.2 50.5 54.5
Tetracycline 36.1 37.9 35.6 36.4
Doxycycline 47.5 48.3 53.5 50
Vancomycin 97.4 100 98 100
Teicoplanin 97.5 100 98 100
Quinupristin/dalfopristin 12.1 3.4 7.9 4.5
Linezolid 96.1 97.9 97.5 97.1
Antimicrobial Agent
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Penicillin 0.06 0.12 100 94.4
Cefuroximeb 0.12 0.25 100d 94.4d
Cefprozil 0.5 1 100d 94.4d
Cefpodoxime 0.25 0.5 100d 94.4d
Cefotaximec 0.12 0.25 100 100
Cefepime 0.12 0.25 96.6 94.4
Erythromycin 0.25 >8 62.1 61.1
Azithromycin 0.12 >16 66.7 60
Clarithromycin 0.25 >32 75 62.5
Clindamycin 0.12 >8 72.4 72.2
Levofloxacin 1 >2 100 100
Gatifloxacin 0.5 0.5 100 100
Garenoxacin 0.06 0.12 — —
Chloramphenicol 4 4 100 100
Tetracyclinee >8 >8 48.3 33.3
Trimethoprim/sulfamethoxale <0.5 >1 NA NA
Linezolid 1 2 100 100
Quinupristin/ dalfopristin 1 4 86.2 83.3
Vancomycin 0.5 0.5 100 100
S. pneumoniae (1561/497)
Amoxicillin 0.06 1 98.2 98.8
Penicillin 0.03 2 69.3 (11.9)f 78.5 (4.6)f
Cefuroximeb 0.06 4 84.5 93.5
Cefprozil 0.25 8 84.1 93.1
Cefpodoxime <0.03 2 84.4 93.8
Cefotaximec 0.03 0.5 98.3 98.6
Cefepime 0.06 1 97.5 99.2
Erythromycin 0.25 2 87.1 88.5
Azithromycin 0.12 2 88.5 91.4
Clarithromycin 0.25 1 87.5 89.2
Clindamycin 0.06 0.25 94.2 94.6
Levofloxacin 1 1 99.8 100
Gatifloxacin 0.25 0.5 99.7 100
Garenoxacin 0.06 0.06 — —
Chloramphenicol <2 4 95.6 98.2
Tetracyclinee <2 >16 79.5 80.5
Trimethoprim/sulfamethoxale <0.5 4 60.5 49.7
Linezolid 1 1 100 100
Quinupristin/ dalfopristin 0.5 0.5 100 100
Vancomycin 0.25 0.5 100 100
Viridans group (124/36)
Amoxicillin 0.12 4 66.1 80.6
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a. Interpreted by NCCLS criteria [6]; b. Percentage of susceptible strains defined by cefuroxime axetil (oral)
[6]; c. Also indicates susceptibility spectrum of ceftriaxone [6]; d. Susceptibility is predicted by the penicillin
result [6]; e. Includes susceptible and intermediate isolates [6]; f. Percentage of isolates showing high level
resistance (MIC ≥2 µg/ml) [6].
Penicillin 0.06 2 66.1 80.6
Cefuroxime 0.25 8 66.1d 80.6
Cefprozil 1 8 66.1 80.6
Cefpodoxime 0.12 >4 66.1d 80.6
Cefotaximec 0.12 2 85.7 100
Cefepime 0.25 2 89.5 94.4
Erythromycin 0.25 2 65.3 72.2
Azithromycin 0.12 1 84.7 78.9
Clarithromycin 0.25 0.25 92.9 100
Clindamycin 0.06 0.12 91.9 97.2
Levofloxacin 1 2 100 100
Gatifloxacin 0.25 0.5 100 100
Garenoxacin 0.06 0.12 — —
Chloramphenicol <2 4 97.6 100
Tetracyclinee <4 >16 69.4 72.2
Trimethoprim/sulfamethoxale <0.5 2 NA NA
Linezolid 1 1 100 100
Quinupristin/ dalfopristin 0.5 1 96 97.2
Vancomycin 0.5 1 100 100
Table 11a. Antimicrobial activity and spectrum of drugs tested against ESBL-producing Escherichia coli and
Klebsiella pneumoniae in the year 2001 throughout Latin America and in Brazil alone
Pathogen (no total/Brazil)/ Latin America Brazil















BJID 2004; 8 (February) 71
www.bjid.com.br















sulfamethoxazole 17.1     a
Klebsiella pneumoniae (122/63)
Cephalosporins
Cefazolin   0.8   0
Cefuroxime   2.5   1.6
Cefoxitin 71.3 71.4




Ampicillin   0   0
Aztreonam 15.6   3.2
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Table 11b. Antimicrobial activity and spectrum of drugs tested against ESBL-producing E. coli and K.
pneumoniae in the year 2001 throughout Latin America from patients with bloodstream infections and lower
respiratory tract infections.
Pathogen/           % Susceptible strains (number of isolates tested)
             Latin America                  Brazil
E. coli Bacteremia Pneumonia Bacteremia Pneumonia
(27) (a) (a) (a)
Cephalosporins
Cefazolin 22.2 a a a
Cefuroxime 25.9 a a a
Cefoxitin 59.3 a a a
Ceftriaxone 48.1 a a a
Ceftazidime 48.1 a a a
Cefepime 66.7 a a a
Other β-lactams a a a
Ampicillin 0 a a a
Aztreonam 51.9 a a a
Ticarcillin/clavulanate 22.2 a a a
Piperacillin/tazobactam 66.7 a a a
Imipenem 100 a a a
Meropenem 100 a a a
Aminoglycosides a a a
Amikacin 81.5 a a a
Gentamicin 59.3 a a a
Tobramycin 44.4 a a a
Fluoroquinolones a a a
Ciprofloxacin 40.7 a a a
Levofloxacin 48.1 a a a
Gatifloxacin 44.4 a a a
Garenoxacin 37 a a a
Others a a a
Tetracycline 33.3 a a a
Trimethoprim/
sulfamethoxazole 18.5 a a a
Klebsiella pneumoniae Bacteremia Pneumonia Bacteremia Pneumonia
(69) (30) (35) (13)
Cephalosporins
Cefazolin   0   3.3   0   0
Cefuroxime   2.9   3.3   2.9   0
Cefoxitin 71 76.7 74.3 69.2
Ceftriaxone 14.5 26.7 8.6   7.7
Antimicrobial agent
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Ceftazidime 23.2 56.7 22.9 30.8
Cefepime 46.4 56.7 37.1 38.5
Other β-lactams
Ampicillin   0   0   0   0
Aztreonam 10.1 36.7   2.9   7.7
Ticarcillin/clavulanate   2.9 10   2.9   0
Piperacillin/tazobactam 37.7 66.7 37.1 53.8
Imipenem 100 100 100 100
Meropenem 98.6 100 97.1 100
Aminoglycosides
Amikacin 62.3 76.7 77.1 76.9
Gentamicin 23.2 36.7 28.6 30.8
Tobramycin 11.6 20 17.1   0
Fluoroquinolones
Ciprofloxacin 66.7 80 71.4 69.2
Levofloxacin 71 83.3 71.4 69.2
Gatifloxacin 71 83.3 71.4 69.2
Garenoxacin 65.2 80 71.4 69.2
Others
Tetracycline 49.3 73.3 51.4 69.2
Trimethoprim/
sulfamethoxazole 37.7 60 31.4 53.8
Table 11c. Antimicrobial activity and spectrum of drugs tested against ESBL-producing E. coli and K. pneumoniae
collected throughout Latin America and in Brazil alone, from January 1997 to December 2001
 Pathogen (no. total/Brazil)/ Latin America Brazil
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Cefazolin   1.6   1.4






Ampicillin   0   0
Aztreonam 17.6 14.4
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Table 11d. Antimicrobial spectrum of drugs tested against ESBL-producing E. coli and K. pneumoniae isolated
from January 1997 to December 2001 from patients with bacteremia and pneumonia
Pathogen/           % Susceptible strains (number of isolates tested)
            Latin America  Brazil
E. coli Bacteremia Pneumonia Bacteremia Pneumonia
(123) (30) (28) (11)
Cephalosporins
Cefazolin   8.1    0 10.7   0
Cefuroxime 11.4   3.3 10.7   0
Cefoxitin 60.2 73.3 75 100
Ceftriaxone 30.1 10 17.9   0
Ceftazidime 43.9 53.3 25 54.5
Cefepime 63.4 43.3 57.1 45.5
Other β-lactams
Ampicillin   0   0   0   0
Aztreonam 33.3 10 21.4 18.2
Ticarcillin/clavulanate 14.6   0 17.9   0
Piperacillin/tazobactam 54.5 43.3 50 45.5
Imipenem 100 96.7 100 100
Meropenem 100 100 100 100
Aminoglycosides
Amikacin 69.9 70 71.4 90.9
Gentamicin 43.9 30 42.9 36.4
Tobramycin 27.7 11.5 22.2   0
Fluoroquinolones
Ciprofloxacin 52.8 56.7 71.4 90.9
Levofloxacin 56.9 56.7 82.1 90.9
Gatifloxacin 57.7 60 82.1 90.9
Garenoxacin 60.3 47.1 73.3 a
Others
Tetracycline 30.1 46.7 35.7 63.6
Trimethoprim/
sulfamethoxazole 25.2 37.9 21.4 45.5
Klebsiella pneumoniae Bacteremia Pneumonia Bacteremia Pneumonia
(405) (142) (156) (65)
Cephalosporins
Cefazolin   1   2.1   1.3   0
Cefuroxime   8.1   2.8   6.4   0
Cefoxitin 75.3 70.4 79.5 76.9
Ceftriaxone 18.5 14.8 15.4  6.2
Ceftazidime 27.9 24.6 37.2 18.5
Antimicrobial agent
76 BJID 2004; 8 (February)
www.bjid.com.br
Cefepime 49.6 47.9 44.9 47.7
Other β-lactams
Ampicillin   0   0   0   0
Aztreonam 17.5 15.5 16.7   7.7
Ticarcillin/clavulanate   7.2   6.3   7.7   3.1
Piperacillin/tazobactam 34.6 37.3 41.7   38.5
Imipenem 99.8 99.3 100 100
Meropenem 99.5 98.6 99.4 98.5
Aminoglycosides
Amikacin 59.3 67.6 64.1 73.8
Gentamicin 29.9 36.6 31.4 38.5
Tobramycin 12.2 14.8 15.6 12.1
Fluoroquinolones
Ciprofloxacin 79.5 73.9 85.3 80
Levofloxacin 83.2 76.8 85.3 80
Gatifloxacin 84.9 76.1 87.2 80
Garenoxacin 80.8 77.3 78.8 78.7
Others
Tetracycline 49.8 54.2 63.5 55.4
Trimethoprim/
sulfamethoxazole 44.6 52.5 34.6 50
resistance among pneumococci, are less frequently
described in Latin America [1].
The main antimicrobial resistance problems the Latin
American countries are presently facing are multidrug
resistant (MDR) non-fermentative Gram-negative
bacilli (Acinetobacter spp. and P. aeruginosa) and
ESBL-prodcing Enterobacteriaceae [1,3,8,9,11-13].
Pseudomonas aeruginosa was the third and the fifth
most frequently isolated pathogen in general and from
blood stream infections, respectively. In addition,
resistance rates were very high for all antimicrobial
agents evaluated, except polymyxin B, which was
evaluated since January 2001 only (Tables 2, 4, 6, and
8). The prevalence of isolates resistant to all
antimicrobial agents except the polymyxins has been
increasing continuously since the program started in
1997 [12]. Additionally, P. aeruginosa resistance rates
were slightly higher among isolates collected in the
Brazilian centers (Tables 2, 4, 6, and 8).
Acinetobacter spp. is much more prevalent and
presented higher rates of antimicrobial resistance in
Latin America, when compared to other regions
evaluated by the SENTRY Program [1]. However,
resistance rates to the carbapenems imipenem and
meropenem were lower than those presented by P.
aeruginosa (Tables 2, 4, 6, and 8). Besides these two
carbapenems, other reasonable therapeutic options for
empirical therapy of Acinetobacter spp. infections are
the polymyxins and sulbactam. The SENTRY Program
started evaluating these compounds in 2001 (polymyxin
B) and 2002 (sulbactam), and the in vitro activity of
these antimicrobial agents will be presented in future
publications [14].
The rates of ESBL-producing Enterobacteriaceae,
especially K. pneumoniae and E. coli, are among the
highest in the world (Tables 2, 4, 6, 8, and
11)[1,3,8,9,11] In addition to resistance to
cephalosporins, broad-spectrum penicillins and
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monobactam, these isolates have also shown high
rates of resistance to most antimicrobial agents,
including aminoglycosides and fluoroquinolones.
Although the fluoroquinolones remained active against
some ESBL-producing K. pneumoniae (61.7% to
87.7% susceptible), the carbapenems meropenem and
imipenem remained the most reliable options for
empirical therapy of infections due to ESBL-
producing strains in the region (Table 11).
Other important resistance problems among
Enterobacteriaceae include fluoroquinolone resistance
due to altered target among E. coli [15]; and stably
derepressed (AmpC) β-lactamases mediated resistance
among Enterobacter cloacae, Citrobacter freundii,
and other clinically important species. Ciprofloxacin
susceptibility rates were as low as 85.5% among E. coli
isolated from blood stream infections and 78.1% among
isolates from patients hospitalized with lower respiratory
tract infections (Tables 4 and 8).
Chromosomaly-inducible β-lactamases (AmpC or
Bush group I) are produced by most
Enterobacteriaceae species; however, some species,
including E. cloacae, C. freundii, Serratia
marcescens and indol-positive Proteus (“SPICE” or
“CESP” group), can produce large amounts of these
enzymes and have become resistant to third-generation
cephalosporins, broad-spectrum penicillins and
monobactams. In our study, E. cloacae resistance to
ceftazidime, which indicates the production of the
AmpC β-lactamase, was as high as 42.9% (Table 4).
Cefepime (84.9 – 96.6% susceptibility) and the
carbapenems imipenem and meropenem (92.9 – 100%
susceptibility) remained very active against E. cloacae
and these other pathogens in the hospitals evaluated
by the SENTRY program (Tables 2, 4, 6, and 8).
Among Gram-positive cocci, oxacillin resistance
among staphylococci has remained an important
problem in Latin America; however, rates varied
significantly from hospital to hospital, even within a
specific country. The vast majority of ORSA strains
showed cross-resistance to most of the antimicrobial
agents evaluated, except vancomycin, teicoplanin,
quinupristin/dalfopristin and linezolid. Resistance to
these agents was not detected among S. aureus isolates
(only a small number of isolates had intermediate-
resistance to teicoplain or quinupristin/dalfopristin);
however, decreased susceptibility to teicoplanin was
relatively common among CoNS (90.3% susceptibility;
Table 9).
The prevalence of glycopeptide-resistant
enterococci remained low in the Latin American
hospitals evaluated by the SENTRY Program (97.5%
susceptibility in general) and its occurrence is usually
linked to clonal dissemination of unique strains
[1,10,16].
The prevalence of penicillin-resistant pneumococci
varied significantly among the Latin American countries
evaluated, and it was especially low in Brazil (only
4.6% with high-level resistance; Table 10). Macrolide
resistance rates were around 10% to 12%, with
approximately half of the erythromycin resistant isolates
showing cross-resistance to clindamycin (MLSB
phenotype). Tetracycline resistance rates were relatively
elevated (around 20%), while resistance rates to
trimethoprim/sulfamethoxazole were very high,
especially in Brazil (49.7% susceptibility; Table 10).
Fluoroquinolone resistance was very rare among
pneumococci (99.7% susceptibility to gatifloxacin) and
it was not detected among other streptococci species
(Table 10). β-hemolytic streptococci remained very
susceptible to penicillin and all other β-lactams evaluated.
However, macrolide resistance was detected among the
isolates of this pathogen (erythromycin susceptibility
of 92.8% and 96.6% throughout Latin America and
in Brazil, respectively). As expected, viridans group
streptococci showed the highest rates of resistance
among streptococci, with only 66.1% of the Latin
American isolates being considered susceptible to
penicillin.
Among the active surveillance systems, the SENTRY
Program has incorporated extensive molecular strain
typing and resistance genotyping as a means of providing
additional information that may be useful for
understanding pathogenic microorganisms worldwide
[1,17]. In any surveillance program the phenotypic
characterization of microorganisms and identification of
epidemic clusters of certain species and resistance
phenotypes is the primary role of the microbiology
Antimicrobial Surveillance Program Report: Latin American and Brazil
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laboratory. In this way, the surveillance laboratory serves
as an “early warning system”, alerting the participating
institutions of a potential problem with resistant organisms
in a variety of patient populations [18].
The rapid emergence and dissemination of numerous
drug resistances among bacteria has raised the
necessity for controlling these pathogens in hospitals
on a global scale; and the determination of clonality
within a phenotypically identical resistant clusters will
have a direct impact on the method of corrective
intervention. On a broader scale, identification of
resistant clones with extensive geographic range may
provide insight into strain virulence and pathogenesis;
and also may result in broader public health
interventions, such as vaccination and antimicrobial
restrictions aimed at limiting the spread of the pathogen
and associated resistance problems [1].
Molecular methods may also be used to detect
specific antimicrobial resistance genes (resistance
genotyping) in a wide variety of organisms and when
coupled with DNA fingerprinting have made substantial
contributions to our understanding of the genetics of
antimicrobial resistance and the spread of resistance
determinants in the SENTRY Program medical centers
[7,15,19].
The main purpose of this report was to present a
comprehensive tabular analysis of the antimicrobial
susceptibility data of bacteria collected in the Latin
American medical centers participating in the SENTRY
Program. Antimicrobial resistances may vary
significantly among Latin American countries and
SENTRY Program evaluates only a small number of
medical centers. However, the main objective of this
program was to detect the most important problems
of public health concern within the region and to assist/
guide regional intervention programs. The data
presented here allow the identification of these principal
resistance problems and the comparison of the in vitro
activity and spectrum of a large number of antimicrobial
agents not often tested in most hospitals. Lastly, we
emphasize that empirical therapy should be guided by
local susceptibility data when those are available, but
in the absence of such information, surveillance data
can help with therapeutic choices.
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